TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 2 Randomized, Double -Blind, Placebo -Controlled, Cross -Over Study to Evaluate 
Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral 
Doses of TAK -831 in Adult Subjects With Schizophrenia
Sponsor: Millennium Pharmaceuticals, Inc, a who lly owned subsidiary o f Takeda 
Pharmaceut ical Co mpany, Ltd
40 Landsdowne Street
Cambridge MA 02139
USA
Study Number: TAK-831-2001
Compound: TAK-831
Date: 14January 2020 Version/Amendment 
Number:06
Amendment History: 
Date Amendment Number Amendment Type Region
28 April 2017 Initial Protocol Not applicable Global
08 September 2017 Amendment 01 Nonsubstantial Global
11 October 2017 Amendment 02 Substantial Global
30 May  2018 Amendment 03 Substantial Global
17 December 2018 Amendment 04 Substantial Global
19September 2019 Amendment 05 Substantial Global
14January 2020 Amendment 06 Substantial Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
NCT #: [STUDY_ID_REMOVED]
TAK -831
Study No. TAK -831-2001 Page 2of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALTABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 7
2.0 STUDY SCHEMATIC .................................................................................................. 12
2.1 Protocol  Amendment No. 06 Summary  of Changes ................................................. 13
3.0 SCHEDULE OF STUDY PR OCEDURES .................................................................... 14
4.0 INTRODUCTION ......................................................................................................... 16
4.1 Background ............................................................................................................. 16
4.2 Clinical Background ................................................................................................ 17
4.3 Rationale for the Proposed Study ............................................................................. 18
4.4 Benefit/Risk Profile .................................................................................................19
5.0 TRIAL OBJECTIVES AND ENDPOINTS ................................................................... 21
5.1 Trial Object ives....................................................................................................... 21
5.1.1 Trial Primary  Objective ...................................................................................... 21
5.1.2 Trial Secondary  Objectives ................................................................................ 21
5.2 Endpoints ................................................................................................................. 22
5.2.1 Primary Endpo ints............................................................................................. 22
5.2.2 Secondary  Endpo ints.......................................................................................... 22
5.2.4 Safety Endpo ints................................................................................................ 22
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 23
6.1 Study  Design ........................................................................................................... 23
6.2 Rationale for Study  Design, Dose, and Endpoints .................................................... 24
6.2.1 Rationale of Study  Design and Regimen ............................................................ 24
6.2.2 Rationale for Dose ............................................................................................. 25
6.2.3 Rationale for Endpoints ...................................................................................... 25
6.2.4 Critical Procedures Based on Study  Object ives: Timing of Procedures ............... 29
6.3 Study  Design/Dosing/Procedures Modificat ions Permitted Within Protocol 
Param eters ............................................................................................................... 29
6.4 Study  Beginning and End/Co mpletion..................................................................... 30
6.4.1 Definit ion of Beginning o f the Study .................................................................. 30
6.4.2 Definit ion of End of the Study ........................................................................... 30
6.4.3 Definit ion of Study  Com pletion......................................................................... 30
6.4.4 Definit ion of Study  Discont inuat ion................................................................... 30
6.4.5 Criteria for Premature Terminat ion or Suspension of the Study .......................... 30

TAK -831
Study No. TAK -831-2001 Page 3of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 32
7.1 Inclusio n Cri teria..................................................................................................... 32
7.2 Exclusio n Cri teria.................................................................................................... 33
7.3 Exclud ed Medicat ions, Supplements, Dietary  Products ............................................ 35
7.4 Diet, Fl uid, Act ivity.................................................................................................37
7.4.1 Diet and Fluid .................................................................................................... 37
7.4.2 Activity.............................................................................................................. 37
7.5 Criteria for Di scontinuati on or Wi thdrawal  of a Subject ........................................... 37
7.6 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 38
7.7 Subject Replacement ................................................................................................ 38
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 39
8.1 Clinical Study  Drug .................................................................................................39
8.1.1 Clinical Study  Drug Labeling ............................................................................. 39
8.1.2 Clinical Study  Drug Inventory  and Storage ........................................................ 39
8.1.3 Clinical Study  Drug Blinding ............................................................................. 39
8.1.4 Randomization Code Creation and Storage ........................................................ 39
8.1.5 Clinical Study  Blind Maintenance/Unblinding Procedure ................................... 39
8.1.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ............................... 39
8.1.7 Ancillary  Supplies .............................................................................................. 40
9.0 STUDY PROCEDURES ............................................................................................... 41
9.1 Administrative Procedures ....................................................................................... 41
9.1.1Inform ed Consent Procedure .............................................................................. 41
9.1.2 Inclusio n and Exclusio n Cri teria......................................................................... 42
9.1.3 Medical History /Dem ographics .......................................................................... 42
9.1.4 Prior and Concomi tant Medicat ion Review ........................................................ 42
9.2 Clinical Procedures and Assessments ....................................................................... 42
9.2.1 Full Physical Examinat ion.................................................................................. 42
9.2.2 Psychiatri c Examinat ion..................................................................................... 42
9.2.3 Height and Wei ght............................................................................................. 42
9.2.4 BMI ................................................................................................................... 43
9.2.5 Vitals (Body  Tem perature, Heart Rate, Blood Pressure) ..................................... 43
9.2.6 12-Lead ECG ..................................................................................................... 43
9.2.7 C-SSRS .............................................................................................................. 44
9.2.8 CDSS ................................................................................................................. 44
9.2.9 PANSS .............................................................................................................. 44
TAK -831
Study No. TAK -831-2001 Page 4of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL9.2.10 Study  Drug Administration ................................................................................ 45
9.2.11 Cogni tive Assessments ....................................................................................... 45
9.2.12 ERPs .................................................................................................................. 45
9.2.13 Delay EBC Test .................................................................................................45
9.2.14 AE Monitoring ................................................................................................... 46
9.2.15 Laboratory  Procedures and Assessments ............................................................ 46
9.3 Biomarker, PK, PD, and , Samples .................................................................... 47
9.3.1 PK Measurements .............................................................................................. 48
9.3.2 Biomarker Measurem ents................................................................................... 48
9.3.4 Conf inement ...................................................................................................... 50
10.0 ADVERSE EVENTS .................................................................................................... 51
10.1 Definit ions and El ements of AEs ............................................................................. 51
10.1.1 SAEs .................................................................................................................. 53
10.1.2 Speci al Interest AEs ........................................................................................... 54
10.2 AE Procedures ......................................................................................................... 54
10.2.1 Assigning Severit y/Intensit y of AEs ................................................................... 54
10.2.2 Assigning Causalit y of AEs ................................................................................ 55
10.2.3 Start Date ........................................................................................................... 55
10.2.4 End Date ............................................................................................................ 55
10.2.5 Pattern of Adverse Event (Frequency) ................................................................ 55
10.2.6 Action Concerning Study  Drug .......................................................................... 55
10.2.7 Outcom e............................................................................................................ 56
10.2.8 Collect ion and Reporti ng of AEs, SAEs, Special Interest AEs, and DILI ............ 56
10.2.9 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties.....58
11.0 STATISTICAL METHODS ................................ .......................................................... 59
11.1 Statistical and Analyt ical Plans ................................................................................ 59
11.1.1 Analysis Sets ...................................................................................................... 59
11.1.2 Analysis of Demographics and Other Baseline Characterist ics........................... 59
11.1.3 PK Analysis ....................................................................................................... 59
11.1.4 PD Analysis ....................................................................................................... 60
11.1.5 Safety Analysis .................................................................................................. 61
11.2 Interim Analysis and Criteria for Early Terminat ion................................................ 62
11.3 Determinat ion of Sample Size .................................................................................. 62
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 63

TAK -831
Study No. TAK -831-2001 Page 5of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL12.1 Study -Site Moni toring Visit s................................................................................... 63
12.2 Protocol  Deviat ions.................................................................................................. 63
12.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 63
13.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 64
13.1 IRB and/or IEC Approval ........................................................................................ 64
13.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 65
13.3 Subject Confidentialit y............................................................................................ 66
13.4 Publicat ion, Di sclosure, and Clinical Study  Registrati on Policy ............................... 66
13.4.1 Publicat ion and Disclosure ................................................................................. 66
13.4.2 Clinical Study  Registrati on................................................................................. 67
13.4.3 Clinical Study  Resul ts Discl osure....................................................................... 67
13.5 Insurance and Co mpensation for Injury .................................................................... 67
14.0 ADMINISTRATIVE AND R EFERENCE INFORMATION ......................................... 68
14.1 Administrative Informat ion...................................................................................... 68
14.1.1 Study  Contact Informat ion................................................................................. 68
14.1.2 INVESTIGATOR AGREEMENT ...................................................................... 69
14.1.3Study -Related Responsibilit ies........................................................................... 69
14.1.4 List of Abbreviat ions......................................................................................... 70
15.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 72
15.1 CRFs (El ectronic and Paper) .................................................................................... 72
15.2 Record Retention ..................................................................................................... 72
16.0 REFERENCES .............................................................................................................. 74
17.0 APPENDICES ............................................................................................................... 78
LIST OF IN -TEXT TABLES
Table 6.a Part 1: Study  Schedule ....................................................................................... 24
Table 7.a Excluded Medicat ions and Dietary  Products ...................................................... 36
Table 9.a Primary Specimen Collections ........................................................................... 48
Table 10.a Takeda Medically Significant AE List ................................................................ 54
TAK -831
Study No. TAK -831-2001 Page 6of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALLIST OF APPENDICES
Appendix A Responsibilit ies o f the Invest igator ..................................................................... 78
Appendix B Elements of the Subject Informed Consent ......................................................... 80
Appendix C Invest igator Consent to Use of Personal Informat ion.......................................... 83
Appendix D Pregnancy and Contraception ............................................................................. 84
Appendix E Detailed Descript ion of Amendments to Text ..................................................... 88
TAK -831
Study No. TAK -831-2001 Page 7of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL1.0 STUDY SU MMARY
Millennium Pharmaceuticals, Inc, a wholly owned 
subsidiary of Takeda Pharmaceutical Company, Ltd
40 Landsdowne Street
Camb ridge MA 02139
USACompound:
TAK -831
Study Number: 
TAK -831-2001Phase: 2
Protocol Title: A Phase 2 Randomized, Double -Blind, Placebo -Controlled, Cross -Over Study to Evaluate 
Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK -831 in Adult 
Subjects With Schizophrenia
Study Design:
This study is a randomized, double -blind, placebo -controlled, 2 -period crossover phase 2 study to evaluate the 
pharmacodynamic (PD) effects, safety, tolerability and pharmacokinetics (PK) of multiple daily oral doses of 
TAK -831 in adult patients with schizophrenia.
Effect s of up to 2 dose levels of TAK -831 or placebo will be assessed. Each treatment will be administered daily for a 
period of 8 consecutive days, separated by a 14- to 21 -day washout. The planned dose levels of TAK -831 to be 
evaluated will be 500 and 50 mg. 
The study will consist of 2 treatment periods, and visits to the clinic at the following times: (1) Screening Period (Days 
-30 to -3) covering full medical, neurological, and psychiatric examinations; (2) Treatment Visits and inpatient stays: 
On Day -2 of Periods 1 and 2, subjects will be admitted to the clinic for 2- night stays; on Day -2, subjects will undergo 
baseline clinical assessment procedures and cognitive battery assessment. On Day -1, subjects will receive the 
baseline EEG and EBC assessments. In Period 1, those who continue to meet all eligibility criteria will be randomized 
via an interactive response technology (IRT) system to 1 of 2 treatment sequences. On Day 1, subjects will undergo 
predose blood PK/PD samples, first dosing, and postdose blo od draws, after which they will be discharged from the 
clinic to continue dosing at their residence. Subjects will receive double -blind treatment from Days 1 through 8 
(inclusive) with completion of efficacy and PK/PD -related assessments on Days 7 and 8 of each treatment period; and 
(3), a washout period between Treatment Periods 1 and 2 lasting between 14 to 21 days.
Subjects will be adults between ages 18 and 60, with a Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM -5) diagnosis of schizophrenia who are receiving stable antipsychotic therapy (no increase or decrease 
>25% in dose in the preceding 2 months), and stable negative symptoms, as measured by the Positive and Negative 
Syndrome Scale (PANSS) during Screening and Baseline ( no fluctuations in PANSS negative symptom factor score 
[NSFS] >25%). PANSS total score will not exceed 90 points and the NSFS will be at least 15. Subjects with 
extrapy ramidal signs o r depressive symptoms will be excluded.
Additional screening assessments include physical and neurological examinations, clinical laboratory and 
electrocardiogram (ECG) measures, a toxicological screen, Screening for suicidality and depression using the 
Columbia Suicide Severity Rating Scale (C -SSRS) and the Calgary Depression Scale Score (CDSS), respectively, 
assessment of extrapyramidal symptoms will be performed with the Simpson Angus Scale (SAS), and the presence of 
dyskinesias will be assessed with the Abnormal Involuntary Movement Scale (AIMS).
Clinical laboratory testing, PK and D- and L -serine sample collection will be performed as per the schedule of events. 
If caregiver accompaniment is required, an adult caregiver will be permitted to attend clinical assessment visits with 
the study  participant. After completion of the initial treatment period, subjects will participate in a washout period 
lasting between 14 to 21 days. After the second treatment period, a final follow -up safety  assessment visit will be 
conducted approximately 10 to 14 days after the last administration of study drug.
During the double -blind treatment periods, subjects will arrive at the clinic on Day 7 of each Treatment Period, as 
required (see schedule of events for details), to receive study drug and/or undergo specified study procedures. Study 
drug for Days 2 to 6 m ay be dispensed to the participant to take at their place of residence, or may be dispensed at the 
clinic through a qualified member of the research team. A process for ensuring adherence to study drug intake at the 
TAK -831
Study No. TAK -831-2001 Page 8of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALsubject’s place of residence, such as su pervision by study staff, a caregiver or a mobile device application to remotely 
monitor study drug adherence will be implemented.
A previous version of this protocol was started at a different site and stopped after 1 subject completed all study 
procedure s. The data from that subject, including safety endpoints, will be analyzed separately from those obtained in 
the subjects enrolled in this study.
Primary Objectives:
To determine whether TAK -831 is superior to placebo in improving cerebellar function as measured with the 
average % of conditioned responses during the eyeblink conditioning (EBC) test. 
Secondary Objectives:
To determine whether add -on TAK -831 compared to placebo improves sensor y processing as measured by event 
related potentials (ERPs) mism atch negativity (MMN) and p300. 
To determine whether add -on TAK -831 compared to placebo improves the auditory steady -state response 
(ASSR) to 40 Hz stimulation.
To determine whether add -on TAK -831 compared to placebo improves the composite score of a neur ocognitive 
test battery.
To assess the safety and tolerability of TAK -831. 
To assess the PK of TAK -831.
To assess the PD of TAK -831 by measurement of plasma D -serine and L -serine levels, as well as D -serine: total 
serine ratios.
Subject Population: Adult s between ages 18 and 60, inclusive, with a DSM -5 diagnosis of schizophrenia who are 
receiving stable antipsychotic therapy.
Number of Subjects:
32Number of Sites:
up to 2
Dose Levels:
TAK -831 500 mg and matching placebo once daily 
(QD) for 8 days
TAK -831 50 mg and matching placebo QD for 8 daysRoute of Administration:
Oral
Duration of Treatment:
Eight days in each period.Period of Evaluation:
Total approximately up to 81 days (Screening: 30 days, 
Treatment Period 1: 8 days, Washout 14 to 21 days, 
Treatment Period 2: 8 days, Follow -up: 10 to 14 days)
Main Criteria for Inclusion:
In order to be eligible for study participation, subjects must be: 
Provide written informed consent or from a legally acceptable representative. 
Be judged to be in good health by the investigator, based on clinical evaluations including laboratory safety tests, 
medical history, physical examination, 12 -lead ECG, and vital sign measurements performed at the Screening 
Visit and prior to administration of the initial do se of study drug/invasive procedure.
Between 18 and 60years old, inclusive.
Body weight >45 kg; body mass index (BMI) between 18.5 to 40 kg/m2. 
With stable schizophrenia. 
Receiving stable antipsychotic medication at doses not to exceed risperidone 6 mg or its equivalent. 
Known to be stable with no clinically meaningful change in psychotropic medications for the preceding 2 months 
TAK -831
Study No. TAK -831-2001 Page 9of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALprior to Baseline. 
Have a PANSS Negative Symptom Factor Score (NSFS) ≥15; stable screening and baseline PANSS NSFS scores 
(≤25% change).
Have a PANSS total score ≤90; stable screening and baseline PANSS total score (<20% change).
Willing and able to comply with all study procedures and restrictions.
A female participant is eligible to participate if she is of:
–Nonchildbearing p otential.
–Childbearing potential and agrees to use 2 forms of contraception methods.
–Women of childbearing potential must have a negative pregnancy test at Screening and at Baseline.
A male subject who is nonsterilized and sexually active with a female par tner of childbearing potential must agree 
to use adequate contraception from signing of informed consent throughout the duration of the study and for 
95days after last dose.
Able to swallow study drug in tablet form.
Should a subject require a caregiver t o accompany him/her during the study, the caregiver should be available for 
the full duration of the study.
Main Criteria for Exclusion:
The subject must be excluded from participating in the study if the subject: 
Ongoing disability, medical, neurological, or psychiatric histor y, cognitive impairment or conditions that, in the 
opinio n of the investigator, are of a nature or severity that may interfere with study conduct or clinical 
assessments.
The subject has a recent (within the last 6 months ) diagnosis of panic disorder, depressive episode, or other 
comorbid psychiatric conditions requiring clinical attention based on the DSM -5 and the general psychiatric 
evaluation. 
Substance abuse or dependence (with the exception of nicotine dependence) w ithin the preceding 6 months based 
on the DSM -5 and the general psychiatric evaluation. 
Positive drug screen for disallowed substances at Screening or Baseline.
Evidence of extrapyramidal adverse events as measured by a SAS score >6 at Screening or Baseli ne.
Evidence of depression as measured by a CDSS score >11 at Screening. Subjects with a CDSS score of 9 to 11 
must be discussed with the sponsor and will also be excluded if the item scores are determined to reflect the 
presence of depression rather than schizophrenia negative symptoms.
Evidence of suicidality as measured by a C -SSRS score >3 at Screening or Baseline.
Hearing deficits preventing participation in event related potential testing.
Histor y of brain trauma associated with loss of consciousness for >15 minutes. 
Female subjects who are lactating or pregnant (positive pre -randomization serum pregnancy test) or plan to 
become pregnant during the study.
Received treatment with other exper imental therapies within the preceding 30 days or <5 half -lives prior to the 
first dose.
Unwilling or unable to comply with the requirements of the protocol Subject has a known hypersensitivity to any 
component of the formulation of TAK -831
Subjects known to be positive for hepatitis B surface antigen (HBsAg)-positive, or known or suspected active 
hepatitis C infection. 
Use of disallowed concomitant medications.
TAK -831
Study No. TAK -831-2001 Page 10of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALMain Criteria for Evaluation and Analyses:
All analyses are for comparison between TAK -831 and placebo.
The primary endpoints of the study are:
Average percentage of conditioned responses during the EBC test at Day 8. 
The secondary endpoints will be assessed through evaluation of the following parameters: 
MMN amplitude at Fz (midline frontal elec trode, EEG) at Day 8. 
P300 amplitude at Pz (midline parietal electrode, EEG) at Day 8. 
ASSR at Cz (midline central electrode, EEG) at Day 8. 
BACS Cognitive battery composite score at Day 7. 
Plasma D -serine and L -serine levels, and D -serine:total serine ratio.
TAK -831 plasma concentrations. 
Statistical Considerations:
The 2 -period crossover design for this study will allow for each subject to provide data on each of the 2 active doses as 
well as placebo. The crossover analysis of this design will take into account the within -subject correlation. While some 
subjects may drop from the study before completing all periods, all available data will be used for analyses.
The expected effect size, defined as the ratio between the mean difference between treatme nt and placebo divided by 
the standard deviation of this difference, is 0.6 for the primary endpoint. This effect size is a conservative estimate 
based on data from a previous report, which showed an effect size of 0.74 on the EBC test at 24 hours after in itiation of 
treatment with secretin. 
A frequentist analysis will be done for the full data set, using simulations to adjust for effect of the interim analysis on 
the ty pe 1 error. The results of the primary endpoint will be considered statistically signif icant at either of the 2 doses 
(as applicable) if the one -sided p <0.05, without adjustment for multiplicity (ie, the type 1 error rate will be separately 
controlled for each dose).
In addition, the primary endpoint will be analyzed using a Bayesian normal linear model with treatment sequence, 
period, and treatment as fixed effects and subject within sequence as a repeated factor. The dependent variable is the 
change in response from the period baseline assessment to the final treatment day for each period. The response data 
will be logit transformed before the change is calculated. The Bayesian model will be used to estimate the posterior 
distribution of the treatment effect from each dose (as applicable).
Interim Analysis:
A small group from the sponsor wi ll remain unblinded to treatment assignment during the study for the purpose of 
conducting interim analyses of PD effects. In order to minimize any potential unblinding of investigators, these staff 
will not interact with the investigators or their staff.
A planned unblinded interim analysis of the primary endpoint will be conducted when approximately 14 patients have 
completed the evaluation for the primary endpoint. The site will be allowed to continue enrollment to the high/placebo 
comparison, with the g oal that approximately 16 patients will be randomized by the time the interim analysis is 
complete. (The additional approximately 2 subjects will be included in the final analysis but not the interim.) The 
purpose of the interim PD analysis will be to dete rmine w hethe r to continue enrolling subjects to the 
high-dose/placebo comparison, switch enrollment to the low -dose/placebo comparison, or discontinue enrollment. 
The decision rule will be specified in an interim analysis plan before the data are unblinded for the interim analysis. In 
addition, a decision to switch to the low dose may be made based on safety or tolerability of the high dose .
TAK -831
Study No. TAK -831-2001 Page 11of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALSample Size Justification:
Up to 32 subjects will be enrolled into this 2 -period crossover study. Initially 16 subjects will be randomized to one of 
the 2 sequences comparing the high dose to placebo: high -placebo or placebo -high. Based on the results of an interim 
analy sis, an additio nal 16 subjects may be randomized to one of the 2 sequences comparing the low dos e to placebo: 
low-placebo or placebo -low. This design and choice of sample sizes has been selected to be sensitive to a plausible and 
biologically meaningful range of effect sizes.
TAK -831
Study No. TAK -831-2001 Page 12of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL2.0 STUDY SCHEMATIC
(a) Assessments on Days 7 and 8 may be performed 1 day before or after, (ie, Day 6 or 8 for Day 7 and Day 7 or 9 for 
Day 8).Period 1
Final 
Assessments 
(Day s 7 and 8) 
(a)8 daysTAK -831
or placeboWashout
14 to 21 days 8 day s
Period 1
Predose 
Assessments 
(Day s -2, -1 
and 1)Safety 
Follow -upScreening Period 2
Final 
Assessments 
(Day s 7 and 8) 
(a)Period 2
Predose 
Assessments 
(Day s -2, -1 
and 1)Up to 30 
days10 to 14 days TAK -831
or placebo
TAK -831
Study No. TAK -831-2001 Page 13of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL2.1 Protocol Amendment No. 06 Summary of Changes 
Rationale for Amendment No. 06
This document describes the changes in reference to the protocol incorporating Amendment 
No.06. 
The primary  reason for thi s amendment is to modify  inclusi on criterion 3 to revi se the maximum
subject age from 50 to 60 y ears of age, to allow for increasing pati ent recrui tment.
For specific descript ion of text changes and where the changes are located, see  Appendix E. 
Changes in Amendment No. 06
1.Updated entry criteria.
TAK -831
Study No. TAK -831-2001 Page 14of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL3.0 SCHEDULE OF STUDY PROCEDURES 
ScreeningPeriods 1 and 2 (a)
Safety 
Follow -Up (b)Early 
Termina -
tion VisitPretreat -
ment Day Treatment Day (c)
Study DayDays 
-30to-3 -2 -1 1 2 3 4 5 6 7 8Post-
Treatment 2 
Day 20±2
Administrative Procedures
Confinement X X X
Informed consent X
Inclusion/exclusion 
criteria (d)X X X X
Demographics/ medical 
history X
Medication history X
Concurrent medical 
conditionsX
Clinical Procedures/Assessments
Full physical 
examinationX X X X
Psychiatric examination X
Height X
Weight, and BMI X
Vital signs (oral [floor of 
the mouth]/ tympanic 
temperature) (e)X X X X X X X X
Concomitant 
medications (e)X X X X X X X X
ECG X X X X
C-SSRS X X X X X
CDSS X
SAS X
AIMS X
PANSS X X X
EBC test (f) X X (f)
ERPs (f, g) X X (f)
Resting state EEG (f) X X (f)
BACS cognitive battery 
(f)X X (f)
Dispense study 
medication (h)X
Study  drug dosing (c) (h) X X X X X X X X
AE assessment (e) X X X X X X X X
Laboratory Procedures
Clinical laboratory tests 
(hematology, serum 
chemistry, urinalysis) (i)X X X X
Hepatitis panel (HBsAg 
and Anti -HCV) X
FSH X
Pregnancy test (hCG) (i) 
(j)X X X X X
Drug screen (i) X X X X
TAK -831
Study No. TAK -831-2001 Page 15of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALScreeningPeriods 1 and 2 (a)
Safety 
Follow -Up (b)Early 
Termina -
tion VisitPretreat -
ment Day Treatment Day (c)
Study DayDays 
-30to-3 -2 -1 1 2 3 4 5 6 7 8Post-
Treatment 2 
Day 20±2
PK Evaluations
PK blood collection (m) X X X X
PD/Biomarker Evaluations
Blood collection (D -and 
L-serine) (n)X X X X
AE=adverse event, BMI -body  mass index, ERP=event -related field, FSH=follicle -stimulating hormone, HBcAg=hepatitis B core 
antigen, hCG=human chorionic gonadotropin, HCV=hepatitis C virus, PANSS=Positive and Negative Syndrome Scale.
(a) A washout interval of 14 to 21 days will separate the last dose of study drug in Period 1 and the first dose in Period 2.
(b) A follow -up safety  visit will be conducted 10 to 14 Days post -treatment Period 2.
(c) Assessments on Days 7 and 8 may be performed 1 day before or after (ie, Day 6 or 8 for Day 7 and Day 7 or 9 for Day 8). If the 
Day 8 assessments are conducted on Day 9, study drug dosing duration will be extended for 1 additional day as well.
(d) Inclusion/exclusion criteria will be assessed only in Period 1.
(e) Vital signs, con comitant medications and AE assessment on Days 2 to 6 to be performed only on subjects who attend the clinic 
site for any reason. Vital signs will be conducted for safety only and will not be entered into the database for these visits . 
(f) Day  8 EBC, ERP, and EEG assessments are to be performed at approximately (± 1 hour) the same time as on Day -1, and the 
Day7 BACS cognitive battery assessments are to be performed at approximately (± 1 hour) the same time of day as on Day -2.
(g) Procedures to be conduc ted only in subjects who receive at least 1 dose of study medication and are assessed within 36 hours of 
the last dose.
(h) Study drug intake on Days 2 to 6 may be supervised by a caregiver or family member, conducted at the investigator site or
supervised by a qualified designee. 
(i) These tests can be repeated at any time at investigator discretion.
(j) Serum Beta hCG at Screening and at the Final Visit, at other visits urine Beta hCG determination on women of childbearing
potential only. 
 
 
(m) Blood samples (approximately 4 mL) will be collected from each subject for the determination of plasma concentrations of 
TAK -831 at the following time points: Day 1 (predose and at 0.25 to 2 hours and 3 to 6 hours postdose) , Day 7 (predose and at 0.25 
to 2 hours and 3 to 6 hours postdose), and Day 8 (predose). One additional blood sample will be collected for subjects at the Early 
Termination Visit, if applicable. The sampling schedule may change based on emerging data but w ill not exceed the number of 
planned samples.
(n) Blood sample (6 mL) will be collected for analysis of plasma concentrations of D -and L -serine immediately following PK 
blood collections on Day 1 (predose and 3 to 6 hours postdose), Day 7 (predose and 3 t o 6 hours postdose), and Day 8 (predose). 
Time of sample collection, time since last dose administered and time of last meal should be recorded for each sample collect ion. 
Samples may be analyzed for other amino acids, but total blood volume collected will not change.

TAK -831
Study No. TAK -831-2001 Page 16of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and 
behaves. The onset of the disease is usually in late adolescence or early adulthood, it affects up to 
1% of the populat ion and increases to 10% in individuals having a first -degree relat ive suffering 
from the disorder (40% to 65% for ident ical twins) [1-3] . Symptoms of schizophrenia can be 
subdivided into 3 broad classes: positive, negat ive, and cognit ive symptoms [4]. Posi tive 
symptoms include hallucinat ions, delusio ns, and disordered th ought and speech, and can be 
summarized as psychosis. Negat ive symptoms include reduced emotion, reduced abilit y to 
experience pleasure (anhedonia), lack of motivat ion and reduced social interact ion. Finally, 
cogni tive symptom s include poor information processing, impaired abilit y to focus on obj ectives, 
and abnormalit ies of working memory and learning [4]. Deficits in glutamatergic transmissio n are 
hypothesized to play  an important role in the pathophysio logy of  the disorder, parti cularl y in 
relation to the genesis of cognit ive impairment, negative symptoms, and anhedonia [5]. 
While current ly available antipsychotics are broadly effect ive for the treatm ent of posi tive 
symptoms, the treatment of negative symptoms and cognitive deficits of schizophrenia remains a 
major unmet medical need. These are the most disabling aspects of schizophrenia, for which there 
are no approved therapies.
Inhibit ion of D-amino acid oxidase (DAO) is a promising target for the treatm ent of schizophrenia. 
Hypofunction of N-methyl-D- aspartate (NMDA) receptors is considered a potential mechanism in 
the pathophy siology of schizophrenia, which could be mit igated with increased D -serine l evels in 
the brain [6]. Changes in the D -serine levels or D -serine to total serine ratios have b een reported in 
the plasma o f patients with schizophrenia both naive and under drug treatment [7-10] . In addit ion, 
serine racemase (the D -serine generating enzyme) and the NMDA NR2A subunit are among the 
risk genes ident ified from the recent l arge scale geno me-wide associat ion stud iesanalysis, 
indicat ing the bio logical  relevance to schi zophrenia of the genet ic pathway in which DAO sit s 
[11].
DAO is invo lved in D- serine m etabo lism in the brain and has been associated with the regulat ion 
of glutam atergi c neurotransmissio n [12]. Inhibit ion of DAO elevates endogenous D -serine in the 
cerebellum, increasing Purkinje cell long term depressio n via act ivation of glutam ate recep tor
(GluR)2 and/or NMDA receptors with subsequent α -amino -3-hydroxy -5-methyl-4- isoxazo le 
propi onic aci d (AMPA) receptor internalizat ion [13].
Adding to the above evidence of a potential ro le of DAO in the pathophysio logy of schizophrenia, 
a weak inhibitor of DAO, sodium benzoate, demonstrated efficacy in posit ive, negat ive, and 
cogni tive symptoms in a proof -of-concept study  in subjects wi thschizophrenia [14].
While current medicat ions mitigate posit ive symptoms of schizophrenia, persistent negat ive 
symptoms and cognit ive impairment represent areas of unmet med ical need. Moreover, cognit ive 
impairment and negat ive symptoms are associated with funct ional outcom es to a greater degree 
than posi tive symptom s and rem ain an area of focus for the development of novel therapeut ics.
TAK -831
Study No. TAK -831-2001 Page 17of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL4.2 Clinical Background
Two phase 1 clini cal studi es have been conducted in healt hy subjects: a first -in-human study  to 
determine the pharmacokinet ic (PK) profiles of TAK -831 oral  suspensi on after single -rising dose 
(SRD) and m ultiple-rising dose (MRD) administration, as well as the relat ive bioavailabilit y and 
effect of food on the PK of the T1 tablet formulat ion of TAK-831 (TAK -831- 1001); and a study to 
demonstrate DAO target engagement in the brain as measured by  posi tron emissi on tomography  
(PET) (TAK -831-1003). Plasma D -serine levels, TAK -831 plasma concentrations and safet y were 
also evaluated. Since these studies were conducted, a single dose PK and food -effect 
bioavailabilit y study with the T2 tablet formulat ion (TAK -831- 1004) has co mpleted active dosing, 
and a study  examining addit ional es calat ing multiple doses of TAK -831 higher than those 
achieved in the TAK -831- 1001 study  was init iated and is ongoing (TAK -831- 1005).
TAK -831 was safe and well tolerated in 103 healt hy subjects in doses administered in studies 
TAK -831- 1001 and TAK -831-1003. Headache was the mo st commo n treatment -emergent adverse 
event. Headaches were mild to moderate in intensity  and generally self -limit ing. The rate of 
postural  dizziness in TAK -831–treated subj ects did not m arkedly  differ from  the rate observed in 
placebo -treated subjects. There were no concerning trends in laboratory , ECG, or vi tal sign data. 
After both single and mult iple dosing wit h TAK -831 (Study  TAK-831- 1001), increases in the area 
under the effect curve fro m time 0 to 24 hour s of D -serine were dose- dependent; changes in 
D-serine were noticeably higher after mult iple daily doses of TAK -831 400 mg than after mult iple 
daily  doses o f TAK -831 30, 100, and 200 mg. Single oral doses of TAK -831 temporally increased 
plasma concentrations of D -serine in the PET study  (TAK -831- 1003); the results are similar to 
those obtained fro m Study  TAK -831- 1001. 
TAK -831-1004 was a phase 1, randomized, open -label, single -dose, 2 -period crossover study 
designed to characterize the PK of a single dose o f 400 mg of TAK -831 and assess the effect of 
food on the bi oavailabilit y of TAK -831 400 m g when administered as four 100 mg oral tablets of 
the T2 form ulation in 15 healt hy adult subjects. In the TAK -831- 1004 study , there was only  a 
single AE of mild upper respi ratory  tract infect ion, judged to be unrelated to study treatment. One 
subject met criteria for orthostatic hypotension at a single time po int without an accom panying 
report of a dizziness AE. There were no concerning trends in laboratory , ECG, or vi tal sign data. 
Treatment with a single oral dose of 400 mg of TAK- 831 T2 form ulation tem porally increased 
plasma concentration of D -serine, similar to the results obtained in the Study TAK -831- 1001. The 
magnitude and kinet ics of the change in plasma D -serine were similar when the drug was 
administered in either water or nutritional drink. TAK-831 given as a T2 tablet coadministered 
with the nutri tional drink increased mean C maxand AUC ∞values by  35% and 21%, respectively . 
TAK -831- 1005 is an ongoing invest igator and subject blinded, sponsor unblinded, 
placebo -controlled clinical study  progressively assessing independent cohorts of healt hy subjects 
to con tinue evaluat ion of the safet y, tolerabilit y, PK, and pharmacodynamics (PD) of escalat ing 
multiple doses of TAK -831 at doses higher than those achieved in the TAK -831- 1001 study . The 
following study  inform ation is preliminary and is based on blinded adverse event data reported by 
the invest igator and blinded safet y endpo int data in study TAK -831- 1005. Alt hough not expected, 
these data are subject to change upon finalizat ion following study  monitoring, source data 
TAK -831
Study No. TAK -831-2001 Page 18of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALverification, and discrepancy query management prior to database lock. At this t ime, four cohorts 
with 8 subjects each (6 TAK -831 and 2 pl acebo) have completed treatment at dose levels of 100 
mg QD (T2 tablet formulat ion), 600 mg QD (T2 tablet formulat ion), 800 mg QD (oral suspensio n), 
or 1200 mg (oral suspensio n) administered first as a single dose, and then administered for up to 14 
days of mult iple dosing. In addit ion to standard safety  assessments, subjects in three of these 
cohorts underwent catheterized CSF co llection for a 24 hour period starting prior to dosing on Day 
1 single dose treatment and on Day  14 of  multiple dose treatm ent. Nausea and post -lumbar 
puncture syndrome were the most commo n treatment -emergent AEs; nausea in the absence of 
post-lumbar puncture syndro me was reported by one subject in each cohort. All episodes of nausea 
were mild in intensit y and self -limit ing. Two subjects in ea ch of the two first cohorts met 
categori cal cri teria for orthostati c hypotension on at least one assessment; none of these findings 
were associated with an AE of dizziness. There were no concerning trends in laboratory , ECG, or 
vital sign data collected in these cohorts. 
After both single and mult iple dosing wit h TAK -831, there was a notable increase in the area 
under the effect curve fro m time 0 to 24 hours of CSF D -serine for both the 600 mg T2 and 800 mg 
oral suspensi on treatm ent groups when co mpared to placebo; changes in CSF D -serine were 
noticeably higher after mult iple doses of TAK -831 than after administration of a single dose of 
TAK -831. The magnitude of the increase in the area under the effect curve for CSF D -serine was 
similar for both the 600 m g T2 and 800 mg oral suspensio n, suggest ing that the maximal PD effect 
in the CSF was achieved at drug exposures attained with the 600 mg T2 dose and 800 mg 
suspension. Fo llowing once -daily  dosing, mean plasma exposures of TAK -831 were higher (C max: 
1.3-fold and AUC: 1.8 -fold) when dosed as an oral suspension than as T2 tablets. Geometric mea n 
Cmaxvalues were 1466 and 1976 ng/mL with 600 mg QD (T2 tablet formulat ion) and 800 mg QD 
(oral suspensi on), respectively. Mean steady -state exposures (AUC t) over the 24-hour dosing 
interval  were on average 4993 and 8853 ng.hr/mL for the respective 600 and 800 mg QD dosing 
cohorts. The mean 24 -hour TAK -831 PK profile in CSF was parallel to that of plasma and 
observed TAK -831 CSF concentrations were well in agreement wi th the TAK -831 unbound 
fraction in plasma .
Overall, the emerging safet y data fro m the TAK -831-1004 and TAK -831- 1005 studi es are 
consistent with the data collected in prior clinical studies and do not alter the risk profile of the 
compound. 
The safet y data from healt hy subjects cannot be directly generalized for patients with 
schizophrenia. However, no safet y signal has manifested that would prevent addit ional studi es in 
healt hy subjects or in subjects with schizophrenia.
4.3 Rationale for the Proposed Study
TAK -831 i s a highly selective and potent inhibitor of DAO, a peroxiso mal enzyme act ive toward 
neutral  D-amino acids. TAK -831 was shown to increase D -serine levels in the cerebellum o f 
norm al rats and i t also dem onstrated a posit ive effect on cognition and social interact ion in rodent 
cogni tion and behavioral models . TAK -831 i s under development for the treatment of cerebellar 
ataxi a,and cogni tive impairment associated with schizophrenia (CIAS), and negat ive symptoms 
TAK -831
Study No. TAK -831-2001 Page 19of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALof schizophrenia. The proposed study  is aimed at provi ding evidence of pharmacodynamic (PD) 
effects of TAK -831 treatm ent on brain function in subjects with schizophrenia .
A cross -over desi gn was chosen for this study  to minimize the potential impact of inter -subject 
variabilit y on the abilit y todetect a treatment effect of TAK -831. As each subject serves as his/her 
own com parator, cross -over designs tend to have greater power to detect treatment effects 
compared to parallel designs. A placebo control is standard in the evaluation o f novel therap eutics 
for neuropsy chiatri c disorders; as this study  is an add- on to standard therapy  in stable subjects the 
risk of subjects experiencing an exacerbat ion of their underlying condit ion is minimized. 
Preclinical data indicates that PD effects of TAK -831 may be apparent with single doses, 
supporting the short treatment duration period.
4.4 Benefit/Risk Profile
There i s no benefit to subjects in this clinical study.
The fo llowing ri sk mit igation measures will be implemented in this study  with TAK -831. These 
measur es are based on what is known about the mechanism o f action of  TAK -831, nonclinical 
data, and the 2 phase 1 studies conducted to date, and general considerat ions in the development of 
new chemical ent ities. Procedures may be added during the study if neces sary based on evaluat ion 
of any addit ional clinical or nonclinical safet y data.
The dosing and duration of TAK -831 proposed for this study  has been used in prior studies in 
healt hy subjects and have not resulted in a safet y signal that would prevent addit ional studi es.
Acute hypersensit ivity/anaphylact ic reactions to new chemical entit ies are al ways a possible 
risk in any clinical study . Appropri ate procedures should be used to manage such possible 
risks. 
Subjects with a risk of suicide according to the in vestigator’s clinical judgment (or as assessed 
by the Columbia -Suicide Severi ty Rating Scale [15]), or who have made a suicide attempt in 
the previous 12 months, will be excluded fro m this study . The Col umbia -Suicide Se verity 
Rating Scale (C -SSRS) will be administered at prescribed intervals to monitor emergent 
suicidality. Subjects shoul d be m onitored f or any  signs of suicidal  ideation or behaviors, and 
appropriate psy chiatri c intervent ions or other precautions should b e insti tuted, if warranted.
Emesis and diarrhea were reported in laboratory  animals exposed to TAK -831 and in clinical 
studi es in heal thy subjects. Nausea has been observed in clinical studies in subjects taking 
TAK -831, but there has been no consistent re lationship observed between frequency  or 
severit y of nausea and dose of TAK -831, and all reports of nausea at the highest dose 
examined in the TAK -831-1005 study were mild in severit y. Subjects will be informed of these 
findings and instructed to contact t he invest igator for guidance in the management of these 
symptoms and possible ways to mit igate them. 
Postural hypotensio n and dizziness were observed in prior studies in healt hy subjects. 
However, the incidence of dizziness in subjects treated with TAK -831 and placebo was 
similar. In addit ion, some healt hy subjects who received TAK -831 met vi tal signs cri teria 
TAK -831
Study No. TAK -831-2001 Page 20of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALconsistent with orthostatic hypotensio n without accom panying clinical symptoms, although a 
number of these observat ions were considered not related to TAK -831. Subj ects will be 
inform ed of these findings and instructed to contact the invest igator for guidance in the 
management of these symptoms and possible ways to mit igate them . 
Eosinophilic intranuclear inclusio n bodies (EIIBs) were observed in the proximal tubule 
epithelium of the kidneys at doses of ≥10mg/kg/day in rats. The EIIBs were not accompanied 
by apparent necrosis, inflammat ion, or impaired renal funct ion and were not considered 
adverse. Similar findings have been reported in the literatu re and are considered to be 
species -specific to the rat [16]. There have been no findings o f elevations in creat inine in 
clinical studies wit h TAK -831 summarized above; creatinine will cont inue to be measured in 
the clinical studies .
Study  procedure –specific risks include issues relat ing to blood collection for safet y 
assessment/ pharmacokinetic (PK) monitoring (venipuncture may cause bruising), and the 
placement of el ectrocardi ogram  (ECG) pads, wh ich may cause so me local redness and/or 
erythema/i tching. The PD assessments planned for the study , aside from  those requi ring a 
blood draw, are noninvasive and are associated with minimal risk. 
TAK -831
Study No. TAK -831-2001 Page 21of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL5.0 TRIAL OBJECTIVES AND ENDPOINTS
5.1 Trial Objectives
5.1.1 Trial Primar y Objective
To determine whether TAK -831 i s superior to placebo in improving cerebellar funct ion as 
measured with the average % of condit ioned responses during the eyeblink condit ioning 
(EBC) test.
5.1.2 Trial Secondary Objectives
To determine whether add -on TAK -831 com pared to pl acebo improves sensory  processing as 
measured by ERPs mismatch negat ivity (MMN) and p300. 
To determine whether add -on TAK -831 com pared to pl acebo improves the auditory  
steady -state response (ASSR) to 40 Hz stimulation.
To determine whether add -on TAK -831 compared to placebo improves the composite score of 
the BACS battery .
To assess the safet y and tol erabilit y of TAK -831. 
To assess the PK of TAK -831.
To assess the PD of TAK -831 by measurement of plasma D-s erine and L -serine levels, as well 
as plasma D -serine: total serine rat ios. 

TAK -831
Study No. TAK -831-2001 Page 22of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL5.2 Endpoints
5.2.1 Primary Endpoints
Average % of condit ioned responses during the EBC test at Day  8. 
5.2.2 Secondary Endpoints 
MMN amplitude at Fz (electroencephalogram [EEG]) at Day  8. 
P300 amplitud e at midline parietal electrode (Pz) (EEG) at Day  8. 
ASSR at midline central electrode (Cz) (EEG) at Day 8. 
BACS cognit ive battery  com posite score at Day  7.
Plasma D -serine and L -serine l evels, and plasma D -serine:total serine ratio at Day  8.
TAK -831 pl asma concentrati ons.
5.2.4 Safety Endpoints
Percentage of subjects who experience at least 1 treatment -emergent adverse event (TEAE).
Percentage of subjects who meet the markedly abnormal criteria for safet y laboratory  tests at 
least once postdose.
Percentage of subjects who meet the markedly abnormal criteria for vital sign measurements at 
least once postdose.
Percentage of subjects wh o meet the markedly abnormal criteria for safet y ECG parameters at 
least once postdose.
Percentage of subjects with treatment -emergent suicidal ideat ion or sui cidal  behavi or as 
measured using the C -SSRS.

TAK -831
Study No. TAK -831-2001 Page 23of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL6.0 STUDY DESIGN AND DES CRIPTION
6.1 Study Design 
This study is a randomized, double -blind, placebo -controlled, 2- period crossover phase 2 study to 
evaluate the PD effects, safet y, tolerabilit y and PK of mult iple daily  oral doses of TAK -831 in 
adult pati ents wi th schizophrenia. 
Approximately  32 adul t male and fem ale subjects between ages 18 and 60, incl usive, wi th a
current Diagnostic and Statist ical Manual of Mental Disorders, Fifth Edition (DSM -5) diagnosis of 
schizophrenia who are receiving stable ant ipsychotic therapy (no increase, no decrease > 25% in 
dose in the preceding 2 months) will be rando mized in to the study. Subjects will have a PANSS 
NSFS of at least 15 with no fluctuation between Screening and Baseline >25%. PANSS total score 
will not exceed 90 points with no fluctuations between Scre ening and Baseline >25%. Subjects 
with extrapy ramidal  signs or symptom s or depressive symptoms will be excluded. 
Addit ional screening assessments include a physical and neuro logical exam , clinical  laboratory  
and ECG measures, a urine drug screen, and scre ening for sui cidali ty and depressi on using the 
C-SSRS and the Calgary  Depressi on Scale Score (CDSS), respectively. Assessment of 
extrapy ramidal  symptoms will be performed wit h the Simpson Angus Scale (SAS) . The presence 
of dyskinesias will be assessed wit hthe Abnorm al Invol untary  Movement Scal e (AIMS).
During the pretreatment day s (Days -2 and -1), subjects will participate in a baseline assessment 
with a cogni tive battery , PANSS, EEG/ERP m easures, and the EBC test.
Effects of up to 2 dose levels of TAK -831 or pl acebo will be assessed. Each treatment will be 
administered daily  for a peri od of  8 consecutive days, separated by  a 14 -to 21 -day washout (see 
Secti on  2.0Study  Schemat ic). 
The pl anned dose l evels o f TAK -831 to be evaluated will be 500 and 50 mg. 
The study  will consist of 2 treatm ent per iods, and visit s to the clinic at the fo llowing times: 
(1)Screening Period (Days -30 to -3) covering full medical, neurological, and psychiatric 
examinat ions; (2) Treatment Visits and inpat ient stays: On Day -2 of Periods 1 and 2, subjects will 
be admitte d to the clinic for 2 -night stay s; on Day  -2, subjects will undergo baseline clinical 
assessment procedures and cognit ive battery  assessment. On Day  -1, subjects will receive the 
baseline EEG and EBC assessments. In Period 1, those who continue to meet all eligibilit y criteria 
will be rando mized via an interactive response techno logy (IRT) system  to 1 of 2 treatment 
sequences. On Day  1, subjects will undergo predose blood PK/PD samples, first dosing, and 
postdose blood draws, after which they will be discha rged from  the clinic to continue dosing at 
their resi dence. Subjects will receive double -blind treatment from Days 1 through 8 (inclusive) 
with com pletion of efficacy  and PK/PD -related assessments on Day s 7 and 8 of each treatment 
period; and (3), a washou t peri od between Treatm ent Peri ods 1 and 2 last ing between 14 to 21 
days. 
The study  schedule is detailed in  Table 6.a.
TAK -831
Study No. TAK -831-2001 Page 24of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALTable 6.a Part 1: Study Schedule
Screening 
Period PretreatmentDose 
Administration 
Period 1 (a) Washout (b, c)Dose 
Administration 
Period 2 (a) Follow -Up (c)
Day -30 to -3 Period 1 
Days -2, -1, 1Days 1 to 8 Days 9 to 22 Days 1 to 8 Period 2 Day 
20±2
(a) Subjects will be admitted to the clinic on the afternoon of Day -2 of each period for pretreatment assessments. On 
Day -2, they  will receive clinical assessments and cognitive testing, and on Day -1 they  will receive EBC and 
EEG/ERP assessments. On D ay 1, they  will receive the first dose of study medication and predose and postdose PK 
assessments. Study drug for Days 3 to 6 may be dispensed to the participant to take at their place of residence or may 
be dispensed at the clinic through a qualified mem ber of the research team. On Day 7 in the morning, subjects will be 
admitted to the clinic for a 1 night stay. On Days 7 and 8, they will receive drug and specified study procedures.
(b) Washout duration may range from 14 to 21 days based on emerging data.
(c) A follow -up safety  visit will be performed 10 to 14 days after the last dose in Period 2. Subjects may be brought 
back to the study clinic for re -evaluation at any time during the study per investigator’s discretion.
Study  parti cipants will receive daily  study  drug dosing unt il Day 8 of each period. Clinical 
assessments, laboratory  tests and ECG will be repeated after dosing on Days 7 and 8 as per the 
schedule of events. Upon complet ion of the first dosing period, subj ects will enter a washout 
period lasting between 14 to 21 day s and will then return to the study  site to undergo Day  -2 
procedures for the next dosing period. 
Approximately  10 to 14 day s after the l ast dose of study  drug in the second dosing period, a 
follow-up safet y assessment will be performed. 
In the event of a subject prematurely discont inuing the study during one of the study  periods, an 
Early Terminat ion Visit must be conducted, at which the safet y, PK, plasma D -and L -serine 
assessments correspond ing to a Final Visit will be performed. If a subject discont inues the study 
during the washout period, only the procedures corresponding to the fo llow-up safet y assessment 
will be performed.
Subjects who drop out before complet ing 2 treatment periods of th e study  may be repl aced at the 
discreti on of  the study  sponsor.
Subjects who do not meet symptom or medicat ion stabilit y criteria (or other entry criteria that ma y 
be met by  the subject at a future time) may  be considered for rescreening with the approval of the 
sponsor or designee.
Subjects who have been screened but have exceeded the 28 -day Screening Period may proceed in 
the study after a discussio n with the sponsor/designee to obtain approval and to determine whether 
any screening procedures should be r epeated before admission on Day -2 of Period 1.
6.2 Rationale for Study Design, Dose, and Endpoints
6.2.1 Rationale of Study Design and Regimen
The cross -over design was chosen to minimize potent ial confounding fro m inter-subject 
variabilit y of baseline characterist ics and PD measures, as each subject will serve as their own 
TAK -831
Study No. TAK -831-2001 Page 25of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALcontrol . PD m easures were selected based on their potential as translat ional measures fro m 
preclinical TAK -831 efficacy models, due to their linkage to NMDA receptor or cerebellar 
funct ion, or th eir associ ation with relevant aspects of schizophrenia pathophysio logy. The 
select ion of neurocognitive measures was informed by the results of a schizophrenia clinical study 
with a weak DAO inhibitor, sodium benzoate [14]. A small Takeda team will remain unblinded for 
the purposes of conducting interim analyses. Limit ed treatment duration is needed for a cross -over 
design and is consistent with PD effects observed in nonclin ical studies wi th single doses or 
multiple doses up to 14 days . 
6.2.2 Rationale for Dose 
Effects of 2 dose levels of TAK -831 or placebo will be evaluated. The proposed doses of TAK -831 
(500 and 50 mg once daily  [QD]) have been selected based on PK data from th e single -rising 
(SRD)/mult iple-rising dose (MRD) studies (TAK -831- 1001 and TAK -831- 1005), brain target 
occupancy  data f rom the posi tron emissio n tom ography (PET) study  (TAK -831- 1003), PK and 
food effect study  (TAK -831-1004), CSF D -serine data from the TAK -831- 1005 study , and safet y 
data from all clinical studi es after oral  administration of TAK -831 in healt hy subjects. D -serine 
levels at 600 mg QD using T2 tablet and 800 mg suspensio n produced a similar level of CSF and 
plasma D -serine, suggest ing that 600 mg QD produced levels o f D-serine approaching maximal 
DAO inhibit ion in t he brain. The planned dose of 500 mg QD is expected to have D -serine increase 
near the plateau. Preliminary  PK/PD m odeling analyses also showed that the high dose regimen 
resul ted in steady -state exposures associated with mean peak target occupancy o f ≥90%, while the 
lower dose regimen produced daily exposures associated with mean peak target occupancy  of 
≥50%. Both doses are predicted to demonstrate D -serine (PD) effects based on prec linical efficac y 
models. These 2 dose levels may allow characterization of an exposure -response relat ionship wit h 
pharmacodynamic measures. The planned dose regimens are expected to deliver mean exposures 
within the range previously studied in study  TAK -831- 1001 and TAK -831- 1005 that were found 
to be well tolerated. 
6.2.3 Rationale for Endpoints
6.2.3.1 Primary Endpoint
EBC Test
Disrupted cerebellar funct ion has been hypothesized to contribute to schizophrenia 
pathophysio logy by way  of disrupti on of  corti co-cerebellar -thalamic -cortical ci rcuits. Pati ents 
with cerebellar l esions m ay display non -motor defici ts such as impaired attention, language and 
executive funct ion. In schizophrenia, cerebellar abnormalit ies have been found including reduced 
volume of vermis, lobules a nd hemispheres, and reductions in size and densit y of Purkinje cells. In 
addition, cerebellar abnormalit ies are correlated with symptoms and clinical outcomes [17]. 
EBC i s highly conserved amo ng mammalian species and is a commo nly used method to 
investigate cerebellar funct ion [18,19]. In EBC, a condit ioned st imulus (CS), a tone precedes but 
coterminates with an uncondit ioned st imulus (US), an airpuff to the eyelid. Learning is 
TAK -831
Study No. TAK -831-2001 Page 26of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALdemonstrated when an eyeblink (the condit ioned resp onse [CR]) occurs prior to the onset of the 
US. Mult iple studi es have evaluated EBC in schizophrenia with the majorit y indicat ing deficit s 
relative to control subjects [19]. Neural circuits in the cerebellum, including cerebellar cortex and 
interposi tus nucleus are essent ial to the devel opment and m anifestati on of the CR. NMDA 
receptors, in particular the GluN2 subunit, appear to play  a cri tical role for the development of 
EBC. In preclinical studies, TAK -831 1 m g/kg per oral  administrati on improved the rate of 
acquisit ion of the condi tioned response rel ative to untreated and vehicle treated control groups. 
Furtherm ore, i t significant ly co mpensated the deleterious effects of scopolamine (0.3 mg/kg, sc) 
administration on the generation of condit ioned eyelid responses and completely reversed 
scopol amine induced de ficits at 1 m g/kg. 
As acquisit ion of delay EBC is impaired in schizophrenia and hypothesized to be linked to 
cerebellar -cortical circui t function, it may be subject to therapeutic intervent ion with TAK -831 
[18]. Of note, the EBC test has been used previously for the evaluat ion of experimental 
therapeuti cs in schizophrenia [20]. 
6.2.3.2 Secondary Endpoints
ERPs
The ERPs to be measured (via scalp EEG) include the mismatch negat ivity potenti al during the 
oddball paradigm (MMN), and the ASSR task. These tests have been linked to NMDA receptor 
funct ion [21-24 ]and have demonstrated differences between subjects with schizophrenia and 
control  subjects.
MMN is an ERP evoked in response to unattended changes in background stimulat ion. MMN is 
believed to reflect an automat ic process of detecting a mismatch between a deviant stimulus and a 
sensory -memo ry trace. Sm aller amplitudes of MMN have been consistent ly identified in 
schizophrenia subjects, showing promise as a quantitative clinical bio marker of the disease [25]. 
MMN amplitude is sign ificant ly reduced by ketamine [21] and is associated with 
ketamine -induced psychotic experiences [22]. Hence, MMN may index NMDA funct ion in 
humans. Moreover, MMN is associated with cognitive and psychosocial functioning in 
schizophrenia [26]. MMN has demonstrated stability  in clinical populat ions wi th high test -retest 
reliabilit y over 1 year [27,28]. Hence, MMN represents a potentially informat ive probe of sensory 
processes for use in experimental medicine studies of novel therapeut ics. Its association wit h 
NMDA receptor funct ion suggests that it may be sensit ive to modulat ion with TAK -831.
The P300 wave is an ERP component that is elicited by the presentation of a novel, behaviorally 
relevant target stimulus embedded amo ng irrelevant stim uli in a manner similar to MMN, but 
requi ring act ive listening and responding fro m participants. Auditory  stimuli are presented in an 
oddball paradigm consist ing of 1 standard tone and 1 target tone. Subjects are instructed to push a 
button as quickly as possible when they  hear the target tone, but not when they  hear the standard 
tone. P300 reflects allocat ion of attenti on and act ivation of immediate memory. P300 amplitude 
indexes brain act ions when the mental representation of the stimulus environment is updated, 
while P300 l atency indexes st imulus classificat ion speed unrelated to response selection 
TAK -831
Study No. TAK -831-2001 Page 27of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALprocesses. The P300 paradigm can therefore be used to study drug effects on the speed and 
efficiency  of effortful attentional processing and working memory  performance. 
ASSRs are evoked oscillatory responses that are entrained to the frequency and phase of 
temporally  modulated stimuli. Individuals wit h schizophrenia experience subject ive sensory 
anomalies and object ive deficit s on assessment of sensory  function. These deficit s can be 
produced by  abnorm al signaling in the sensory  pathways and sensory  cortex or by  later-stage 
disturbances in the cognit ive processing of such inputs. SSRs can be used to assess the integrit y of 
sensory  pathways including cortical processing. Steady  state response can be maximized when 
delivered as ASSR stimuli at ~40 Hz. Schizophrenia subjects have been shown to have deficits in 
ASSR power and phase locking of approximately 0.5 vs control subjects. ASSR has demonstrated 
adequate test -retest characterist ics in healthy vo lunteers to both evoked power and intertrial phase 
coherence when measured using both a standard EEG array  [29] or using magneto 
electroencephalography [
30]. Therefore, ASSR appears to be a promising surrogate measure to 
evaluate NMDA funct ion in humans.
Cognitive Batt
ery
Cogni tive deficit s are a core, enduring aspect of schizophrenia. Cognit ive deficit s are m ore 
strongly  associated wi th functional outcom es than psychoti c symptoms, yet there are no therapies 
currently approved for their treatment and represent a major u nmet need in the treatment of 
schizophrenia. Mult iple clinical development programs for the treatment of CIAS have not been 
able to successfully demo nstrate adequate evidence of efficacy . Recent ly sodium benzoate, a weak 
inhibitor of DAO, showed efficacy i n multiple cognit ive measures in a small phase 2 study  when 
used as add- on therapy  in schizophrenia subjects [14]. 
D
-and L -Serine
Changes in the D -serine levels or D -serine to total serine ratios have been reported in the plasma o f 
patients wi th schizophrenia, both naive to drug treatment and under drug treatment [7-10] . 
Inhibit ion of DAO elevates endogenous D -serine in the cerebellum and plasma of rats. Analysis o f 
changes in D -serine levels, and D -serine to total  serine rati os will  allow an evaluat ion of PD 
effects, and  
will allow a 
preliminary evaluat ion of the potential utilit y of these bio markers to select for patients that may  
benefit from treatment with TAK -831. 
TAK-831 Plasma Concentrations (or PK)
TAK -831 pl asma concentrations are used to measure TAK -831 PK parameters and build PK/PD 
relationship (see Section 11.1.3 ) .

TAK -831
Study No. TAK -831-2001 Page 28of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL6.2.3.4 Safety Endpoints
TAK -831 has undergone clinical assessments in previous studies. Based on the safet y and 
tolerabilit y pro file observed to date, standard safety endpo ints and moni toring have been included 
in the current study , including AE docum entati on, psychiatri c assessments, laboratory  tests and 
biomarker evaluat ion.

TAK -831
Study No. TAK -831-2001 Page 29of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL6.2.4 Critical Procedures Based on Study Objectives: Timing of Procedures 
For thi s study , collect ing EBC, EEG, cognit ion, PK, and bio markers in subjects with 
schizophrenia are the crit ical procedures. 
On Day  -2, a baseline cognit ive assessment will be conducted. On Day  -1, baseline EBC, and 
EEG based measures will be conducted. Postbaseline EBC test, EEG, and cognit ive testing 
will be performed sequent ially on Days 7 and 8, wit h EBC tested approximately 1 hour 
postdose.
At any postdose tim e point, the cri tical assessments need to be collected as close to the exact 
time point as possible.
All other procedures should be co mpleted as close as possible, either before or after the 
prescribed/scheduled time.
The order of assessments can be changed during the study  with joint agreem ent of  the 
investigator and the sponsor. 
Any nonscheduled procedures required for urgent evaluat ion of  safety concerns take precedence 
over all routine scheduled procedures. 
6.3 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a phase 2 study  to expl ore assessment of PD profile of TAK -831 in humans. Some 
alterati ons from the currently outlined dose and/or dosing regimen may be permitted based on 
newly available data.
In order to accommodate potential unant icipated disruptions to the planned schedule of events, 
subjects will be provided wit h 10 day s of drug supply  for each treatm ent peri od. In case of 
subject unavailabilit y to parti cipate in study  procedures, rescheduling the subject to attend the 
site up to 1 day  earlier or l ater will not be considered a protocol deviat ion.
The timing of planned procedures for asses sment of safet y procedures (eg, vital signs, ECG, 
safet y laboratory  tests) and washout currently outlined in the protocol may be modified during 
the study  based on newly available safet y, tolerabili ty, PK, or PD/bi omarker data. These 
changes will not incre ase the number of study  procedures for a given subject during his/her 
participat ion in the ent ire study . 
Addit ional laboratory  safet y tests m ay be added to blood samples previously  drawn to obtain 
additional safety  information (eg, adding creatine kinase to serum chemistry  panel that was 
already drawn). 
It is understood that the current study may emplo y some or none of the altera tions described above. 
Any alterat ion made to this protocol to meet the study object ives must be detailed by the sponsor in 
a letter to the Study  File and forwarded to the investigator for retention. The letter may be 
forwarded to the inst itutional review board (IRB) /independent ethics committee (IEC) at the 
discreti on of  the invest igator.
TAK -831
Study No. TAK -831-2001 Page 30of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL6.4 Study Beginning and End/Completion
6.4.1 Definition of Beginning of the Study
The overall study  begins when the first subject signs the study  informed consent form.
6.4.2 Definition of End of the Study
The overall study  ends when the l ast subject com pletes the l ast pl anned or follow -up 
visit/interact ion associated with a planned visit, discontinues from the study or is lost to fo llow-up 
(ie, the invest igator is unable to contact the s ubject).
6.4.3 Definition of Study Completion
The primary  object ive of this phase 2 study  is to assess if cerebellar funct ion can be improved by 
add-on TAK -831 therapy  com pared to pl acebo based on the EBC in subjects with schizophrenia.
It is possible that study subjects may not receive all dose levels specified in the protocol, or that the 
study  may be stopped before all planned subjects are enrolled if this object ive is achieved early in 
this study . This is not considered an early terminat ion of the study , but rather an earlier than 
anticipated achievement of the study  objective(s) or study  com pletion. 
6.4.4 Definition of Study Discontinuation
Study  discontinuation due to non-safet y reasons, such as:
A finding (eg, PK, PD, biologic targets, etc) fro m ano ther preclinical or clinical study using the 
study  treatm ent(s) resul ts in the study  being stopped for a non -safet y-related reason. 
Data from co mparator(s), drug(s) of the same class, or methodology(ie s) used in this study  
beco me available and results in the study  being stopped for a non -safet y-related reason. 
The study  is stopped due to non -scientific and non- safet y reasons, such as slow enrollment.
Study  discontinuation due to safet yreasons: 
Early study  terminat ion due to unant icipated concerns of safet y to the study  subjects ari sing 
from clinical or preclinical studies with the study  treatm ent(s), com parator(s), drug(s) of the 
same class, or methodology (ies) used in thi s study .
6.4.5 Criteria for Prematu re Termination or Suspension of the Study
The study  will be com pleted as pl anned unless one or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study .
New informat ion or other evaluat ion regarding t he safet y or efficacy  of the study  medicat ion 
that indicates a change in the known risk/benefit profile for the compound, such that the 
risk/benefit is no longer acceptable for subjects participat ing in the study .
Significant vio lation of Good Clinical Pra ctice (GCP) that com promises the abilit y to achieve 
the primary  study  objectives or compromises subject safet y.
TAK -831
Study No. TAK -831-2001 Page 31of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL6.4.5.1 Criteria for Premature Termination or Suspension of Study Sites
A study  site may  be terminated prematurely  or suspended if the site (including t he invest igator) is 
found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study , or as otherwise permitted by  the contractual  agreem ent.
6.4.5.2 Procedures for Premature Termination or Suspension of the Study or the Participation of 
Study Site(s)
In the event that the sponsor, an IRB/IEC, or regulatory  authority elects to terminate or suspend the 
study  or the parti cipat ion of an invest igational site, a study -specific procedure for early 
terminatio n or suspensio n will be provided by the sponsor; the procedure will be fo llowed by  the 
investigat ional site during the course of terminat ion or study  suspensi on.
TAK -831
Study No. TAK -831-2001 Page 32of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry  criteria, including test result s, need to be confirmed prior to randomizat ion or first dose.
7.1 Inclusion Criteria 
In order to be eligible for participat ion in this study, the subject or caregiver must:
1.Understand the study  procedures and agree to participate by  providing wri tten informed
consent.
2.Be willing and able to comply with all study  procedures and restrict ions (see Sections  7.3and 
7.4for a summary  of restri ctions).
3.Be m ale or a female aged 18 to 60years, inclusive, at the Screening Visit. 
4.Have a body  BMI ≥18.5 and ≤40.0 (kg/m2) at the Screening Visit.
5.Be judged to be in good health by the invest igator, based on clinical evaluat ions including 
laboratory  safety tests, m edical history , physical  examinat ion, 12 -lead ECG, and vital sign 
measurements performed at the Screening Visit and prior to administration of the init ial dose 
of study  drug/in vasive procedure.
6.Meet the fo llowing bi rth control  requi rements:
–Is a m ale subject who i s sterile or agrees to use a barrier method of contraception 
(eg,condom with or without spermicide) fro m study drug administration on the first day o f 
the first dose u ntil 95 days after the last dose of study drug administration. No restrict ions 
are required for a vasectomized male subject provided the subject is at least 1 year 
post-bilateral vasectomy procedure prior to study drug administration on first day of the 
first dose. A m ale subject whose vasectomy procedure was performed less than 4 months 
prior to study  drug administrati on on the first day  of the first dose must fo llow the same 
restri ctions as a nonvasectomized male. Appropriate documentation of surgical pro cedure 
shoul d be provi ded.
–Is a m ale subject who agrees to not donate sperm from study  drug administrati on on the 
first day  of the first dose until 95 days after the last dose of study  drug administrati on.
–Is a female subject with no childbearing potential , defined by at least 1 of the fo llowing 
criteria:
a)Postmenopausal  (defined as 12 m onths of spontaneous amenorrhea in females aged 
>45 y ears, 6 months of spontaneous amenorrhea in females aged >45 years with seru m 
FSH l evels >40 m IU/mL). Appropri ate docum entation of  FSH levels is required.
b)Surgically sterile by  hysterectomy  and/or bilateral  oophorectomy  with appropri ate 
docum entati on of  surgical  procedure.
c)Had a tubal ligat ion with appropri ate docum entati on of  surgical  procedure. 
d)Has a congenital condit ion resul ting in no uterus.
TAK -831
Study No. TAK -831-2001 Page 33of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL–Is a female subject with child -bearing potential must have the fo llowing cri teria:
a)A negat ive pregnancy test at Screening and Baseline.
b)Agrees to use a highly effect ive method of contraception fro m signing of inform ed 
consent throug hout the duration of the study and for 35 days after the last dose. (see 
Appendix Dfor definit ions of hi ghly effective contraception).
c)Is not breastfeeding.
7.Meets a c urrent DSM -5 diagnosis of schizophrenia .
8.PANSS NSFS ≥15, stabl e screening and baseline PANSS NSFS (<25% change).
9. PANSS total score ≤90; stable screening and baseline PANSS total score (<20% change). 
10.Receiving stable (no increase, no decrease >25% in dose in the preceding 2 months) 
antipsychotic medicat ion at doses not to exceed risperidone 6 mg or its equivalent. 
Concomitant treatment with a subtherapeut ic dose of a second antipsychotic may be permitted 
with sponsor or designee approval if used as a hypno tic (maximum  of quetiapine 300 mg or its 
equivalent once daily  at bedt ime) and subject does not show morning sedat ion as per the 
investigator opinio n, but not if it is used for refractory  posi tive psychosis symptoms. Under 
this except ion, the total daily d ose the second antipsychotic will not have to be included in the 
calculat ion of the 6 m g/day  risperi done- equivalent limit.
11.Able to swallow study  drug in tablet form.
12.Shoul d a pati ent requi re a caregiver to accom pany  him/her during the study , the caregiver 
shoul d be available for the full duration of the study .
7.2 Exclusion Criteria
The subject must be excluded fro m participat ing in the study if the subject: 
1.Has parti cipated in another invest igational study  within 30 days prior to the prestudy  
(screening) visit or <5 half -lives pri or to the first dose. The 30 day s window will be derived 
from the date of the l ast study  procedure and/or AE related to the study  procedure in the 
previous study  to the prestudy /Screening Visit of the current study . 
2.Is an emplo yee or immediate family member (eg, spouse, parent, child, sibling) of the study  
site personnel or of the Sponsor.
3.Has a history  of cancer (m alignancy) excluding treated basal cell carcino ma or treated 
stage 0(in situ) cervical carcino ma.
4.Has a history  of significant mult iple and/or severe allergies (eg, food, drug, latex allergy) or 
has had an anaphylact ic reaction or significant intolerabilit y to prescript ion or nonprescript ion 
drugs or food.
5.Subject has a QT interval with Fridericia’s correction method (Q TcF) >450 ms (males) or 
>470 m s (females) confirmed wit h one repeat testing, at the Screening Visit or Check -in.
TAK -831
Study No. TAK -831-2001 Page 34of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL6.Has a posit ive alcoho l or drug screen for disallowed substances, including amphetamines, 
barbiturates, cocaine, marijuana, methadone, methamphetamine, 
3,4-methylenedio xymethamphetamine, phencyclidine, or nonprescribed benzodiazepines or 
opiates. Note: Subj ects testing posit ive for marijuana at Screening may  be eligible for 
participat ion in the study provided that the principal invest igator’s clinical assessment 
indicates that the subject is not a regular user of marijuana, and after discussio n with and 
approval  from the sponsor or designee. Under this circumstance, a patient may either be 
re-screened after a sufficient washout period or m ay continue screening process and a drug 
screen m ust be perform ed on Baseline Day -2 of each treatm ent peri od and at all subsequent 
outpati ent visi ts and verified to be negative prior to conducting any other study  procedures at 
these visit s. If the subject is confirmed to be eligible for randomizat ion at the Day  1 Visi t, the 
central  laboratory  urine drug screen will be performed at all study  visits to confi rm that the 
subject is complying with restrict ions on substances of abuse. Any posit ive urine drug scr eens 
during conduct of the study  must be di scussed wit h the sponsor or designee to determine the 
subject's disposit ion.
7.Has a posit ive pregnancy test or plan to beco me pregnant during the study (female subjects 
only).
8.Is posi tive for HBsAg, hepatit is C ant ibodies, or has HIV by history  (confi rmatory  testing is 
allowed; most sensit ive test should take precedence).
9.Had m ajor surgery , donated or l ost 250 m L of bl ood wi thin 4 weeks pri or to the prestudy  
(screening) visit. 
10.Use of disallowed conco mitant m edicat ions.
11.Is unable to refrain fro m or anti cipates the use of any  medicat ion (except those prescribed), 
including prescript ion and nonprescript ion drugs or herbal remedies beginning approximately 
7 day s prior to administration of the init ial dose of study drug, throughout the study (including 
washout intervals between treatment periods), until the poststudy  visit. There may be certain 
medicat ions that are permitted, see Section  7.3.
12.Unwilling or unable to comply wit h the requirements of the protocol. 
13.Subject has a known hypersensit ivity to any  com ponent of the formulat ion of TAK -831.
14.If male, the subject intends to donate sperm during the course of this study  or bef ore 95 days 
have elapsed since the last dose of study  drug. 
15.Subject has a history  of significant skin reactions (hypersensit ivity) to adhesives, metals or 
plastic.
16.The subject is considered by the invest igator to be at imminent risk o f suicide or injury to self , 
others, or property , or subj ects who wi thin the past year prior to Screening have attempted 
suicide. Subj ects who have posit ive answers on item 4 or 5 on the C -SSRS (based on the past 
year) pri or to randomizat ion are excluded.
TAK -831
Study No. TAK -831-2001 Page 35of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL17.Ongo ing disabilit y, medical , neurol ogical , or psy chiatri c history , cogni tive impairment or 
condi tions that, in the opinion o f the invest igator, may interfere with study  conduct or clinical 
assessments. 
18.The subject has a recent (within the last 6 months) diagnosis of panic disorder, depressive 
episode, or other comorbid psychiatric condit ions requiring clinical attention based on the 
DSM -5 and the general psychiatric evaluation.
19.The subject has a diagnosis of substance use disorder (with the except ion of nicotine 
dependence) within t he preceding 6 months based on DSM -5 and the general psychiatric 
evaluat ion.
20.The subject exhibit s more than a minimal level o f antipsychotic -induced parkinsonism 
symptoms, as documented by  a score on the m odified SAS (excluding item number 10, 
Akathisia) > 6.
21.The subject has evidence of depressio n as measured by a CDSS >11 at Screening. Subjects 
with a CDSS score of 9 to 11 must be discussed with the sponsor and will also be excluded if 
the item scores are determined to reflect the presence of depressio n rather than schizophrenia 
negat ive symptoms.
22.Hearing deficit s that i n the invest igator’s opinio n prevent participat ion in event related 
potenti al testing.
23.History  of brain trauma associated with loss of consciousness for >15 minutes. 
7.3 Excluded Medications ,Supplements, Dietary Products
Subjects m ust be instructed not to take any  medicati ons, including over- the-counter products, 
without fi rst consul ting wi th the investi gator.
Subjects who require treatment with one or more of the specified medications should be excluded 
or discontinued (as appropriate) from the study . If a subject i s prescribed treatment with a 
prohibited medicat ion during the conduct of the study, the invest igator should contact the sponsor 
or desi gnee to revi ew the rel evant clinical informat ion and m edicat ion treatment to determine 
subject disposit ion.
Excluded agents (prescript ion or nonprescript ion) or dietary products are listed in  Table 7.a. Items 
with an ‘X’ indicate restrictions on either chronic or episodic use. Drug classes without an ‘X’ in 
these columns indicate no restrict ions.This table enco mpasses the most commo nly used 
medicat ions; however, it is not a comprehensive list. Ad ditional detailed guidance on 
excluded/allowed medicat ions m ay be provi ded in separate reference documentation provided to 
study  sites.
TAK -831
Study No. TAK -831-2001 Page 36of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALTable 7.a Excluded Medications and Dietary Products
Drug ClassDisallowed (X) During the Study
(sections without [X] indicate no restriction)
Chronic Use Episodic Use Comments or Exceptions
Any investigational drug X X <30 days before Screening or 5 half-lives –
whichever is longer
Narcotic analgesics X Episodic use permitted if prescribed, must 
not be taken within 8 hours. of any study 
efficacy assessment.
Anorexiants (eg, phentermine, benzphetamine, 
phendimetrazine, methamphetamine, 
amphetamine, stimulants, sibutramine, Belviq 
(lorcaserin), Qsymia (phentermine/ topiramate)X X Must be discontinued for ≥30 days prior to 
Screening
Antiarrhythmics of 1C class, quinidine X X
Antibiotics X
Anticholinergics X X Maximum dose of chronic anticholinergic 
treatment is 2 mg/day of benztropine or 
equivalent. 
Antithrombic agents and anticoagulants 
(excluding warfarin, which is excluded)X
Anticonvulsants X X Exception: gabapentin and pregabalin are 
permitted if they are prescribed at a stable 
dose for ≥2 months prior to Screening and 
throughout study treatment. Subjects taking 
other anticonvulsants should not be 
considered for participation in the study, as 
their discontinuation could lead to symptom 
instability.
Antidepressants (excluding tricyclic 
antidepressants, MAOIs, and RIMAs)X Tricyclic anti depressants, MAOIs, and 
RIMAs are excluded, and subjects taking 
them should not be considered for 
participation in the study, as their 
discontinuation could lead to symptom 
instability.
Antihistamines X X Except loratadine, desloratadine, cetirizine, 
levocetirizine, mizolastine, and 
fexofenadine.
Antihypertensives Clonidine NOT allowed.
Antipsoriatic agents X X Topical agents are allowed.
Antipsychotics X Clozapine is excluded; all other treatments 
must adhere to requirements outlined in the 
study  entry  criteria.
As an exception, occasional use of an 
additional dose of the background 
antipsy chotic may be permitted with sponsor 
or designee approval. 
Footnotes are on last table page.
TAK -831
Study No. TAK -831-2001 Page 37of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALTable 7.a Excluded Medications and Dietary Products (continu ed)
Drug ClassDisallowed (X) During the Study
(sections without [X] indicate no restriction)
Chronic Use Episodic Use Comments or Exceptions
Herbal remedies, which are psychoactive (eg, St 
John’s Wort, kava, valerian, ginkgo biloba, 
melatonin)X X Must be discontinued ≥14 days prior to 
randomization.
Sedative hypnotics Barbiturates are excluded. Chronic 
treatment with BZs is allowed up to 3 
mg/day lorazepam or equivalent (BZ 
equivalence standards will be provided in a 
site reference document). Episodic use of 
BZs for the treatment of anxiety or agitation 
as needed is permitted up to 2 mg/day 
lorazepam (or the equivalent dose of another 
benzodiazepine) up to 3 times per week, but 
cannot be taken within 8 hours of the 
administration of study asses sments.
Insulin X X
Mood stabilizers X X
Steroids: Systemic oral or injectable X X As an exception, treatment with local steroid 
injections for orthopedic conditions may be 
permitted with sponsor or designee 
approval.
Topical
Inhalant
Stimulants X X Must be discontinued for ≥30 days prior to 
Screening.
UGT enzyme inhibitors (probenecid and valproic 
acid)Not within 14 days of dosing.
BZ=benzodiazepine, MAOI=monoamine oxidase inhibitor, RIMA=reversible inhibitor of monoamine oxidase type A, 
UGT=uridine 5' -diphosphate -glucuronosyltransferase.
7.4 Diet, Fluid, Activity 
7.4.1 Diet and Fluid
Study  drug can be taken wit h water or milk. Subjects should avo id drinking juices 1 hour before 
and 1 hour after taking study  drug . 
7.4.2 Activity
Subjects will avoid unaccustomed strenuous physical act ivity (ie, wei ght lift ing, running, 
bicycling, etc) fro m the Screening Visit unt il the poststudy  visit.
7.5 Criteria for Discontinuation or Withdrawal of a Subject
1.The subject experiences an AE that requires early termi nation because cont inued participatio n 
imposes an unacceptable risk to the subject’s healt h or the subject is unwilling to continue 
TAK -831
Study No. TAK -831-2001 Page 38of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALbecause of the AE. The primary  reason for di scont inuat ion or wi thdrawal  of the subject form 
the study  or study drug shoul d be recorded in the electronic case report form (eCRF).
2.Drug -Induced Liver Injury (DILI).
Study  medicati on shoul d be discont inued immediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has ret urned to 
norm al/baseline status), if any  of the fo llowing ci rcumstances occur at any  time during 
study  medicat ion treatment:
–Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >8 × upper limit  
of norm al (ULN), or
–ALT or AST >5 × ULN and per sists for more than 2 weeks, or
–ALT or AST >3 × ULN in conjunct ion with elevated total  bilirubin >2 × ULN or INR 
>1.5.
3.Significant protocol deviat ion. The discovery postrando mizat ion that the subject failed to meet  
protocol  entry  criteria or di d not adhere to protocol requirements, and continued participation 
poses an unacceptable risk to the subject’s health. Subject inabilit y to adhere to medicat ion 
intake or study  procedures m ay also be considered a reason for early subject discont inuat ion.
4.Lost to follo w-up. The subject did not return to the unit and mult iple attem pts to contact the 
subject were unsuccessful. Attempts to con tact the subject must be documented.
5.Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from  the study .
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal due to an 
AE should not be recorded in the “voluntary  withdrawal ” category ).
6.Study  terminat ion. The sponsor, IRB/independent ethics committee, or regulatory  agency  
terminates the study .
7.6 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study participat ion at anytime during the study when 
the subject meets the study termination criteria described in Section  7.5. In addition, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
the invest igator. In addit ion, efforts should be made to perform all procedures scheduled for the 
Early Terminat ion Visit. 
7.7 Subject Replacement
If a subject discont inues from the study , a repl acement subject may  be enrolled, if deemed 
appropriate by  the investi gator and Sponsor. The study  site shoul d contact the IRT for the 
replacement subject’s treatment assignment and ident ificat ion number.
TAK -831
Study No. TAK -831-2001 Page 39of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL8.0 CLINICAL STUDY MATER IAL MANAGEMENT
8.1 Clinical Study Drug 
Details regarding the dosage form descript ion and strengths, or composit ion for the 
extemporaneous preparation, of the act ive drug and placebo, can be found in the pharmacy manua l 
or in the referenced co mpounding manual when applicable. Study drug will be packaged to 
support enrollment and replacement subjects as required.
8.1.1 Clinical Study Drug Labeling
Study  drug containers will be affixed with a clinical label in accordance wit h local regulatory  
requi rements.
8.1.2 Clinical Study Drug Inventory and Storage
Study  drug m ust be stored in a secure, limited -access l ocati on under the storage condit ions 
specified on the label and remain in the original container unt il dispensed. The temperature 
excursio n informat ion can be found in the pharmacy manual or in the referenced co mpounding 
manual when applicable. Receipt and dispensing of study  drug m ust be rec orded by  authori zed 
personnel at the study  site.
8.1.3 Clinical Study Drug Blinding
The study  drug blind will be maintained using the IRT.
8.1.4 Randomization Code Creation and Storage 
IRT system will generate the rando mizat ion schedule. All rando mizat ion informat ionwill be 
stored in a secured area, accessible only by  authorized personnel.
8.1.5 Clinical Study Blind Maintenance/Unblinding Procedure
The study  drug blind will be maintained using the IRT.
The study  drug blind shall not be broken by  the investi gator unl ess inf ormation concerning the 
study  drug i s necessary for the medical treatment of the subject. If possible, the medical mo nitor 
shoul d be contacted before the blind is broken. Unblinding will be performed per the standard 
operating procedures of the study  site.
8.1.6 Accountability and Destruction of Sponsor- Supplied Drugs
The invest igator is responsible for keeping accurate records of the study drug received fro m the 
sponsor or designee, the amount dispensed to and returned by the subjects, and the amount 
remaining a t the end of the study . For all  study  sites, the l ocal country  sponsor personnel or 
designee will provide appropriate documentation that must be completed for study  drug 
accountabilit y, return, and destruction .
TAK -831
Study No. TAK -831-2001 Page 40of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL8.1.7 Ancillary Supplies
All ancillary supplies wil l be provi ded by eit her the study  site or the sponsor or desi gnee, based 
upon availabilit y. The list of ancillary supplies and source information can be found in the 
pharmacy manual or in the referenced co mpounding manual when applicable. If provided by th e 
sponsor, unused ancillary supplies will be accounted for and disposed of as directed by the sponsor 
or desi gnee.
TAK -831
Study No. TAK -831-2001 Page 41of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL9.0 STUDY PROCEDURES
The fo llowing sect ions describe the study  procedures and data to be collected as indicated in the 
Schedule of Study Procedur es (Section 3.0). For each procedure, subjects are to be assessed by the 
same investigator or site personnel whenever possible. Please note that it may beco me nece ssary  to 
perform  the f ollowing procedures at unscheduled time periods, per the discret ion of the 
investigator.
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
Inform ed consent m ust be obtained prior to the subject entering into the study  and before an y 
protocol -directed procedures are performed, including requesting that a subject fast for laboratory 
evaluat ions.  informed consent is a co mponent of the overall study  inform ed 
consent . The requirements of informed consent are described in Section 13.2.  
When subjects have performed screening assessments prior to study, the data from screening using 
a generic screening consent form can be used in this study  for those who were subsequent ly 
enrolled, as long as the procedure was performed within the protocol screening to enrollment 
window.
 
9.1.1.1 Assignment of Screening and Randomization Numbers 
All consented subjects will be given a unique screening number that will be used to identify the 
subject for all procedures that occur prior to randomizat ion or allocat ion. Screening numbers must 
not be re -used for different subjects. Any subject who is screened multiple times will be assigned a 
new screening number for each screening event.
All eligible subjects will be rando mized by contacting the IRT for treatment assi gnment. The 
rando mizat ion number will be assigned to each subject; however, it will not be provided to the site 
or entered into the eCRF. The subject ident ification (ID) number will be the number that ident ifies 
the subjects for all procedures. Once a rand omizat ion number is assigned to a subject, it can never 
be reassigned to another subject. A single subject cannot be assigned more than 1 rando mizat ion 
number .
9.1.1.2 Clinical Study Drug Assignment
At the first and subsequent drug -dispensing visits, the invest igator or designee will access the IRT 
to request study  drug for a subject. The medicat ion ID number of the study  drug to be di spensed 
will be provided by the IRT.

TAK -831
Study No. TAK -831-2001 Page 42of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL9.1.2 Inclusion and Exclusion Criteria 
Each subject is assessed through randomizat ion, according to the eligibilit y criteria provi ded in 
Secti on  7.0.
9.1.3 Medical History/Demographics
Qualified site personnel a re to collect subject significant medical history  (past and ongoing) per 
the site’s standard of care and appropriate clinical judgment as well as subject demographics. 
9.1.4 Prior and Concomitant Medication Review
Medicat ions are defined as prescription and ove r-the-counter drugs, vitamin supplements, 
nutraceuticals, and oral herbal preparat ions. Qualified site personnel are to review subject 
medicat ion use.
9.2 Clinical Procedures and Assessments
9.2.1 Full Physical Examination
Qualified site personnel will conduct full physical  including neurol ogical examinat ions. 
9.2.2 Psychiatric Examination
The presence of extrapy ramidal symptoms will be determined using the SAS. The presence of 
dyskinesias will be documented with the AIMS .
9.2.2.1 SAS
The SAS is a clinician -rated assessment of ne uroleptic-induced Parkinsonism consist ing of 10 
items. Item s are anchor -based, rated on a 5 -point scale, and address rigidit y, gait (bradykinesia), 
tremor, gl abellar tap, and salivat ion [36]. The SAS will be administered by a qualified rater at the 
site.
9.2.2.2 AIMS
The AIMS is a clinician -rated assessment of abnormal mo vements consist ing of unobtrusive 
observat ion of the subject at rest (with shoes removed) and several questions or instructions 
directed toward the subject. Using a severit y scale ranging from 0 (none) to 4 (severe), clinicians 
rate dy skinesia in several body regio ns, including the facial area, extremit ies, and trunk. There are 
two items rel ated to dental  status, as well as three global impressio n items assessing overall 
severit y, incapacitat ion, and th e subject’s awareness of abnormal mo vements [37,38] . The AIMS 
raters will be required to meet specific credent ial and educat ional criteria before they  are certified 
to rate for this study . The AIMS will be administered by  a qualified rater at the site.
9.2.3 Height an d Weight
Body  weight and height will be obtained with the subject’s shoes off, and jacket or coat removed.
TAK -831
Study No. TAK -831-2001 Page 43of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL9.2.4 BMI
BMI equals a person’s weight in kilograms divided by  height in meters squared (BMI=kg/m2). 
Body  weight and height will be obtained with the subje ct’s shoes off and jacket or coat removed. 
BMI will be rounded to the nearest whole number according to the standard convent ion of 
0.1to0.4 round down and 0.5 to 0.9 round up.
9.2.5 Vitals (Body Temperature, Heart Rate, Blood Pressure)
Body  temperature will b e measured wi th an oral  (tem perature taken at floor of the mouth) or 
tympanic thermo meter. The same method (eg, oral or tympanic) must be used for all subsequent 
measurements for each individual subject and should be the same for all subjects.
Subjects sho uld rest in a semirecumbent position for at least 5 minutes prior to having vital sign 
measurements obtained. Vital signs will include heart rate (HR) and sy stolic and diastolic blood 
pressure. The same method (eg, same size cuff, manual or automated) must be used for all 
measurements for each individual subject and should be the same for all subjects. 
9.2.6 12-Lead ECG
Speci al care must be taken for proper lead placement by qualified personnel. Skin should be clean 
and dry  prior to l ead pl acement. Subj ects m ay need to be shaved to ensure proper lead placement. 
Female subjects may need to remove their bra. 
Subjects should be resting in a semirecumbent position for at least 5 minutes prior to each ECG 
measurement.
QTcF will be used to calculate QT intervals in th is study .
Prior to each treatm ent peri od/cohort, a predose ECG will be obtained on Day  -2. Thi s 
measurement will be used as the baseline. The principal invest igator should arrange to have a 
study  cardi ologist available as needed to review ECG tracings with abnorm alities.
During each treatment period, if a subject demonstrates an increase in QTcF interval ≥40 msec 
compared wi th a predose baseline measurement, the ECG will be repeated within 5 minutes. The 
average value of the QTcF interval fro m the 2 ECGs wi ll represent the value at that time po int. If 
the average QTcF interval increase from Baseline for any  postdose time point is ≥40 msec, the 
subject will cont inue to be monitored by repeat 12 -lead ECGs every 60 minutes for at least 4 hours 
or until the QTcF is wit hin 40 msec of the baseline value. If prolongat ion of the QTcF interval 
≥40msec persists, a consultation wit h a study  cardi ologist may  be appropri ate and the Sponsor 
shoul d be notified.
If the QTcF interval is 500 m sec on repeat measurements, the Sponsor should be notified and the 
ECGs should be reviewed by a cardio logist. The subject should be monitored (until the QTcF is 
<500 msec) or should be considered for transfer to a location where closer monitoring is available.
If the subject has unstable hemodynamics, or has any clinically significant dysrhyt hmias noted, the 
subject should be immediately transferred to an acute care setting for definit ive therapy . 
TAK -831
Study No. TAK -831-2001 Page 44of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALIf repeat ECGs are required, the clinical site will decide whether to leave the electrodes in place or 
mark the posit ion of the electrodes for subsequent ECGs. To mark the position o f the electrodes, 
12-lead electrode sites will be marked on the skin of each subject with an ECG skin marker pen to 
ensure reproducible electrode placement.
The fo llowing ECG param eters will be recorded: HR, PR -interval, QRS -durati on, QT -interval, 
QTcF -interval, and the interpretation of the ECG profile by the principal investigator.
9.2.7 C-SSRS
The C -SSRS was developed by researchers at Columbia Universit y as a t ool to he lp systemat ically 
assess suicidal ideat ion and behavior in subjects during participat ion in a clinical study of 
centrally -acting drugs. The C -SSRS i s composed of 3 quest ions addressing suicidal behavior and 
5questions addressing suicidal ideat ion, wi th subquestions assessing the severit y. The tool  is 
administered via an interview with the subject.
Suicidali ty will be assessed by  the use of the C -SSRS, a 3 -part scale that measures suicidal 
ideat ion (eg, subject endorses thoughts about a wish to be dead or h as other thoughts of suicide), 
intensity of ideation (frequency, durat ion, controllabilit y, deterrents, and reasons for ideat ion), and 
suicidal behavi or (actually, interrupted, and aborted attempts at suicide). Two versions of the 
C-SSRS will be used in this study : the Screening/Baseline C -SSRS Lifet ime and the 
Since-Last-Visit C -SSRS. 
9.2.8 CDSS
The CDSS was developed to assess symptoms of major depressive disorder in patients with 
schizophrenia, and specifically  designed to assess comorbid depressive symptoms. The CDSS 
consists of nine items: depressed mood, hopelessness, self -deprecat ion, guilt y ideas of reference, 
pathol ogical guilt, depressio n worse in the morning, early  wakening, sui cide and observed 
depressio n. The items on the CDSS are all t ypical depress ive symptom s and do not appear to 
overl ap wi th the negative symptoms of schizophrenia. The tool is administered via an interview 
with the subject.
9.2.9 PANSS
The PANSS is an interview -based measure of the severit y of psychopathol ogy in adults wit h 
psychoti c disorders. The measure is comprised of 30 items and 3 scales: the Posit ive scale assesses 
hallucinat ions, delusio ns, and related symptoms; the Negative scal e assesses em otional 
withdrawal , lack of m otivati on, and similar symptom s; and the General Psychopathology  scale 
addresses other symptoms such as anxiet y, som atic concern, and disorientation. An anchored 
Likert scale from  1 to 7, where values of 2 and abov e indicate the presence of progressively  more 
severe symptoms, is used to score each item. Individual items are then summed to determine 
scores for the 3 scales, as well as a total score. A Composite scale score (Posi tive scale score minus 
Negative scale s core) can al so be calculated to show the relat ive valence of posit ive and negative 
symptoms. Total time required for the PANSS interview and scoring is approximately 30 to 
40minutes [39-41 ]. PANSS raters will be required to meet specific training and educat ion criteria 
TAK -831
Study No. TAK -831-2001 Page 45of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALbefore they  are certified to rate for this study . In addi tion, raters will receive specific training and 
education regarding all o f the assessments prior to study  initiation.
9.2.10 Study Drug Administration
This is a double -blind study; therefore, TAK -831 or matching placebo will be administered orally, 
once a day  for 8 days in a blinded fashio n.
9.2.10.1 Monitoring Subject Treatment Compliance
Com pliance will  be assessed via study  drug coun t and subject or informant report. Subjects will 
also be required to bring study medicat ion containers to each clinic visit, regardless of wh ether the 
study  medicat ion container is empt y.
All subjects who are noncompliant should be reinstructed about the dosing requirement during 
study  contacts. The authori zed study  personnel conducting the re -education must document the 
process in the subject source records. Subjects will be required to bring study medicat ion 
containers/unused medicat ions to the site visit during the study .
9.2.11 Cognitive Assessments
In order to obtain early est imates of potential treatment effects of TAK -831 on cognit ive funct ion, 
the BACS battery  will be included in this study  [42]. These neurocognit ive do mains may  be 
potenti ally improved by TAK -831 based on preclinical efficacy data as well as the results of the 
phase 2 sodium benzoate study  [14]. 
The set of tests is of approximately  35 to 40 minutes duration and may  be conducted using eit her 
paper and pencil or a comparable versio n delivered electronically [43]. 
9.2.12 ERPs
This test takes approximately 45 minutes.
The ERPs to be measured (via scalp EEG) include the MMN potential during the oddball paradig m 
(MMN), the P300 wave during the oddball task, and the ASSR task. These tests have been linked 
to NMDA receptor function [21-24]and have demonstrated differences between subjec ts wi th 
schizophrenia and control subjects. Further details will be provided in the manual of procedure 
(MOP) for event related potentials and EEG based measures.
Frequency analysis during resting state will be recorded as quantitative electroencephalogram as 
indicated in the Schedule of Study  Procedures (Secti on  3.0).
9.2.13 Delay EBC Test
EBC enables evaluat ion of cerebellar -dependent learning and is the p rimary endpo int in this study. 
Briefly, the procedure i nvolves an init ial set of 8 uncondit ioned st imuli (uncondit ioned stimulus: 
corneal  air puff, 50 msec, 10 psi at source) presented with an intertrial interval o f 15seconds. The 
acquisit ion phase will t hen fo llow, consisting of 5 blocks of trials (mean intertrial interval = 
15seconds; range = 10 to 20 seconds). Each block will contain 18 trials in which the condit ioned 
TAK -831
Study No. TAK -831-2001 Page 46of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALstimulus (1 KHz tone; 400 msec; sound pressure level: 80 dB) will be paired wit h the 
uncondit ioned st imulus and 2 trials in which the condit ioned st imulus will be presented alone. In 
trials in which the condit ioned and uncondit ioned stimuli are paired, the uncondit ioned st imulus 
air puff will be coterminated with the condit ioned stimulus t one. The overall durat ion of this task is 
between 30 to 60 minutes. Further details will be provided in the MOP for EBC test (including 
modificati ons f or administrati on at the Screening Visit).
9.2.14 AE Monitoring
AE m onitoring begins following signing of informed consent. Changes in subject healt h status 
from baseline assessment to trial drug administration should be captured in the subject’s medical 
history . A com plete descri ption of  AE collect ions and procedures is provided in Sect ion  10.0.
9.2.15 Laboratory Procedures and Assessments
Laboratory  samples will be collected in accordance with acceptable laboratory  procedures. 
Samples will  be taken on the day s stipulated in the Schedule of Study Procedures (Section  3.0).
9.2.15.1 Clinical Laboratory Tests
Hematology
Hem atology will cons ist of the fo llowing tests:
Erythrocy tes (red blood cells) Hemoglobin
Hematocrit Platelets
Leukocytes (white blood cells [WBCs]) with absolute 
differential
Urinalysis
Urinalysis will consist of the fo llowing tests:
Protein Glucose
Blood Nitrite
Urine microscopy  will be perform ed if urinalysis is abnormal. Microscopy  consists of red blood 
cell/high -power field, white blood cell/high- power field, and casts.
TAK -831
Study No. TAK -831-2001 Page 47of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALChemistry 
Chemistry  evaluat ions will consist of the fo llowing standard chemistry  panel:
Albumin Alkaline phosphatase 
ALT AST
Blood urea nitrogen Calcium
Carbon dioxide Chloride
Creatinine Glucose
Gamma -glutamyl transferase Sodium
Potassium Bilirubin (total), if above ULN total bilirubin will be 
fractionated
Protein (total)
9.2.15.2 Diagnostic Screening
Serum
Serum  diagnostic evaluat ions will include the fo llowing tests:
β-hCG (females only) FSH (females only)
Hepatitis Screen (HBsAg, HCV antibody)
Urine
A urine drug screen will include the fo llowing tests: 
Amphetamines 3,4-methy lenedioxy -methamphetamine 
Barbiturates Methadone / Metabolite
Benzodiazepines Opiates
Bupreno rphine / Metabolite Oxycodone / Oxymorphone
Cannabinoids Phency clidine
Cocaine / Metabolites
9.3 Biomarker, PK, PD, and , Samples
Samples for PK and PD (D -and L -serine) will be collected as specified in the Schedule of Study  
Procedures (Section 3.0). Please refer to the Labor atory  Manual for informat ion on the collect ion, 
processing, and shipment of samples to the Central Laboratory .
The decisio n as to which plasma and/or urine samples collected will be assayed for evaluat ion of 
PK/bio markers will be determined by the Sponsor (eg, samples at lower doses may not be assayed 
if samples at higher doses reveal undetectable drug concentrations). If indicated, these samples 

TAK -831
Study No. TAK -831-2001 Page 48of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALmay also be assayed and/or pooled for assay  in an exploratory  manner for m etabo lites and/or 
additional biomarker s.
It is ant icipated that the total blood volume drawn for the study  will be approximately  220 ml . 
Primary specimen co llection parameters are provided in Table 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary 
Specimen 
Derivative Description of Intended Use
Blood sample for PK Blood Plasma Plasma sample for PK analysis
Blood sample for PD assessment (D -
and L -serine)Blood Plasma Plasma sample for PD analysis
9.3.1 PK Measurements 
9.3.1.1 PK Sample Collection
Serial blood sam ples (one 4 -mL sample per scheduled time) for PK analysis o f TAK -831 pl asma 
concentrations will be co llected into chilled Vacutainers containing the anticoagulant potassi um 
ethylenediamine tetraacetic acid (K 2EDTA), as specified in Schedule of Study  Procedures (See 
Secti on 3.0) .
The actual  date and time of each PK sample co llection as well as the date and time of study drug 
dosing for the most recent dose will be recorded accurately in the eCRF.
Instructi ons for sample co llection, processing and shipment are provided in the laboratory manual.
9.3.1.2 Bioanalytical Method s
Plasma concentrations o f TAK -831 will be measured by  a validated hi gh-performance liquid 
chromatography  (HPLC) wi th tandem  mass spectrom etry.
9.3.2 Biomarker Measurements 
9.3.2.1 PD Sample Collection
Serial blood sam ples (one 6 -mL sample per scheduled time) for PD (D -serine and L -serine) 
analysis of TAK -831 will be collected into chilled Vacutainers containing the anticoagulant 
K2EDTA, according to the schedule shown in in Schedule of Study  Procedures (See Section 3.0).

TAK -831
Study No. TAK -831-2001 Page 49of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALThe actual  time of sample co llection, time since last dose was administered, and time since last 
meal will be recorded on the source document and eCRF.
Instructi ons for sam ple processing and shipment are provide d in the laboratory  manual .
9.3.2.2 PD Analysis
Plasma concentrations o f D-and L -serine will be measured by a validated HPLC with tandem 
mass spectrometry . Additional D -and L -amino acids may  also be analyzed, including but not 
limited to alanine.
9.3.2.3 PD Parameters
PD parameters will be determined for all evaluable subjects. Actual sampling times, rather than 
scheduled sampling times, will be used in all computations invo lving sampling t imes. The PD 
param eters of pl asma D -and L -serine, and the ratio of D -serine to total  serine in plasma will be 
assessed . Individual PD data may  be combined wi th other study  data and analyzed using a 
popul ation PK/PD modeling approach.

TAK -831
Study No. TAK -831-2001 Page 50of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL9.3.4 Confinement
The study  will include 2 inpati ent stays at the clinic in each period. The first will be 2 day s 
(including night stay s on Days -2 to -1) and the second will be on D ays 7 to 8 (including a night 
stay on Day  7). In between these stay s, subjects will report to the study  site as and when requi red 
per schedule of assessments.

TAK -831
Study No. TAK -831-2001 Page 51of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL10.0 ADVERSE EVENTS
10.1 Definitions and Elements of AEs
An AE is defined as any untoward medical occurrenc e in a clinical invest igation subject who has 
signed inform ed consent to participate in a study; it does not necessarily  have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically sig nificant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whether or 
not it is considered related to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions underlying disease should not be considered AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ionor a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG param eters maybe consider ed to be AEs if they  are 
judged to be clinically  significant (i e, if som e act ion or intervent ion is required or if the 
investigator judges the change to be bey ond the range of normal physio logic fluctuati on). A 
laboratory  re-test and/or continued monitorin g of an abnormal value are not considered an 
intervent ion. In addit ion, repeated or addit ional noninvasive testing for verificat ion, evaluatio n 
or monitoring of an abnormalit y is not considered an intervent ion.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signin g of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X -ray, etc) shoul d NOT be recorded as an AE unless 
related to a study  procedure. However, if t he subject experiences a worsening or complicat ion 
TAK -831
Study No. TAK -831-2001 Page 52of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALof such a concurrent medical history  condi tion, the worsening or complication should be 
recorded appropriately as an AE (worsening or complicat ion occurs after informed consent is 
signed). Invest igators sh ould ensure that the event term recorded captures the change in the 
condi tion (eg, “worsening of…”).
If a subject has a pre -exist ing episodic condit ion (eg, asthma, epilepsy), any occurrence of an 
episode should only be captured as an AE if the episodes be come more frequent, serious, or 
severe in nature, that is, invest igators should ensure that the AE term recorded captures the 
change from in the condit ion (eg “worsening of…”).
If a subject has a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthri tis), 
worsening of the condit ion should only be captured as an AE if occurring to a greater extent to 
that which would be expected. Again, investigators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of… ”).
Worsening of AEs:
If the subject experiences a worsening or complicatio n of an AE aft er the first administration of 
study  medicat ion or after any  change in study  medicat ion, the worsening or complicat ion 
shoul d be recorded as a new AE. Investigators sh ould ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Changes in severit y of AEs:
If the subject experiences a change in the severit y of an AE that is not associated with a change 
in study  medicati on, the event shoul d be captured once with the maximum severit y recorded.
Prepl anned surgeries or procedures:
Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedu re is performed 
early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the worsening o f 
the condi tion shoul d be captured appropriately  as an AE. Com plicati ons resul ting fro m any 
planned surgery  should be reported as AEs.
Elect ive sur geries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as AEs but should be documented in the subject’s source documents. 
Com plicat ions result ing from an elect ive surgery shoul d be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a study  subject, at a dose above that which is assigned to that individual subject 
according to the study protocol. It is up to the investigator or the reporting physician to decide 
whether a dose is to be considered an overdose, in consultation wit h the Sponsor.
All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the eCRF, i n order to capture this important safet y information consistent ly in the 
TAK -831
Study No. TAK -831-2001 Page 53of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALdatabase. AEs associated with an overdose will be documented on AE CRF(s) according to 
Secti on  10.0.
Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Sect ion  10.2.8 .
In the event of drug o verdose, the subject should be treated symptomat ically.
10.1.1 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4.Results in persistent or significant DISABILIT Y/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately l ife 
threatening or fatal or does not result in hospitalization.
Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
TAK -831
Study No. TAK -831-2001 Page 54of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALTable 10.a Takeda Medically Significant AE List 
Term
Acute respiratory failure/acute respiratory 
distress syndromeHepatic necrosis
Acute liver failure
Torsade de pointes / ventricular fibrillation / 
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal product Toxic epidermal necrolysis/
Stevens -Johnson syndromeNeuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and fo llowed up in the same manner (see Section  10.2.8.3 ).
10.1.2 Special Interest AEs
No AEs of special interest have been ident ified for this compound.
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The different categories o f severit y/intensity are:
Mild: An adverse event that is usually transient and may requi re only  minimal 
treatm ent or therapeutic intervent ion. The event does not generally interfere 
with usual  activi ties of  daily living.
Moderate: An adverse event that is usually alleviated with addit ional specific therapeut ic 
intervent ion. The event in terferes wi th usual  activi ties of  daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: An adverse event that interrupts usual activit ies of daily living, or significant ly 
affects clinical status, or may require intensive therapeutic intervention.
TAK -831
Study No. TAK -831-2001 Page 55of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL10.2.2 Assigning Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Related: An AE that fo llows a reasonable temporal sequence fro m admi nistrati on of  a 
drug (including the course after withdrawal o f the drug), or for which a causal 
relationship is at least a reasonable possibilit y, ie, the relati onship cannot be 
ruled out, al though factors other than the drug, such as underlying diseases, 
complicat ions, conco mitant drugs and concurrent treatments, may also be 
responsible.
Not Rel ated: An AE that does not follow a reasonable temporal sequence fro m ad ministration 
of a drug and/or that can reasonably be explained by  other factors, such as 
underlying diseases, complicat ions, conco mitant medi cations and concurrent 
treatm ents.
10.2.3 Start Date 
The start date of the AE is the date that the first signs/symptoms were noted by  the subject and/or 
investigator.
10.2.4 End Date 
The end date of the AE is the da te at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.2.5 Pattern of Adverse Event (Frequency) 
Episodi c AEs (eg, headache) or those which occur repeatedly over a period of consecutive days are 
defined as intermittent. Al l other events are continuous or once.
10.2.6 Action Concerning Study Drug 
Drug withdrawn -a study  medicati on is stopped due to the particular AE.
Dose not changed -the particular AE did not require stopping a study  medicat ion.
Unknown -only to be used if it has not been possible to determine what action has been taken.
Not applicable -a study  medicat ion was stopped for a reason other than the particular AE 
eg,the study  has been terminated, the subject died, dosing with study  medicat ion had not y et 
started o r dosing wit h study  medicat ion was already  stopped before the onset of the AE.
Dose reduced -the dose was reduced due to the particular AE.
Dose increased -the dose was increased due to the particular AE.
Drug interrupted -the dose was interrupted due t o the particular AE .
TAK -831
Study No. TAK -831-2001 Page 56of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL10.2.7 Outcome 
Recovered/reso lved -subject returned to first assessment status with respect to the AE.
Recovering/resolving -the intensit y is lowered by  one or m ore stages: the diagnosis has or 
signs/symptom s have alm ost disappeared; the a bnorm al laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the subject died fro m a cause other 
than the particular AE with the condit ion rem aining “recovering/resolving.”
Not recovered/not resolved -there is no c hange in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/symptoms or laboratory  value on the l ast day  of the observed 
study peri od has beco me worse than when it started; is an irreversible congenital ano maly; the 
subject died fro m another cause with the particular AE state remaining “Not recovered/not 
resolved.”
Recovered/ Reso lved with sequelae -the subject recovered fro m an acute AE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal  - an AE that is considered as the cause of death.
Unknown -the course of the AE cannot be fo llowed up due to hospital change or residence 
change at the end of the subject’s participation in the study .
10.2.8 Collection and Reporting of AEs, SAEs, Special Interest AEs, and DILI
10.2.8.1 Collection Period
Collect ion of AEs (ie, AEs, SAEs, Special Interest AEs, and DILI) will co mmence at the time the 
subject signs the informed consent. Routine collection of AEs will continue unt il the follow-up 
visit 10 to 14 days after the last dose of invest igational product. For subjects who discont inue prior 
to the administration of study  medicati on, AEs will  be followed unt il the subject discontinues 
study  participati on. 
10.2.8.2 Reporting AEs
At each stu dy visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects exp eriencing an 
SAE prior to the first exposure to invest igational product must be monitored un til the symptom s 
subside and any clinically relevant changes in laboratory values have returned to Baseline or there 
is a sat isfactory  explanat ion for the change. N onseri ous AEs that begin prior to the first exposure 
to invest igational product, related or unrelated to the study procedure, need not be fo llowed-up for 
the purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the us e of the study medicat ion 
or not, m ust be m onitored until the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
TAK -831
Study No. TAK -831-2001 Page 57of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALchanges observed. All AEs will be documen ted in the AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug treatment. The fo llowing informat ion 
will be documented for each event:
Event term .
Start and end date and time.
Pattern of AE (frequency).
Seve rity/Intensi ty.
Causalit y (Invest igator’s opinio n of the causal relationship between the event and 
administration of study  drug[s]).
Action taken with trial drug.
Outcom e of event.
Seriousness.
10.2.8.3 Reporting SAEs
When an SAE occurs through the AE collection period it shoul d be reported according to the 
procedure outlined below:
A Takeda SAE form must be co mpleted, in English and signed by the invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment.
The S AE form should be transmitted within 24 hours to the attention of the contact listed in 
Appendix 14.1.1 .
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the Sponsor if considered related to study  parti cipat ion.
Reporting of SAEs that begin before first administration of investigational product will fo llow the 
same procedure for SAEs occurring on treatment.
SAE Follow -Up
If informat ion not available at the time of the first report becomes available at a later date, the 
investigator should complete a fo llow-up SAE form  or provi de other wri tten docum entati on and 
TAK -831
Study No. TAK -831-2001 Page 58of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALfax it immediately wit hin 24 hours of receipt. Co pies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The time lines 
and procedure for follow -up reports are the same as those for the init ial report.
10.2.8.4 Reporting Special Interest AEs 
No AEs of special interest have been ident ified for TAK -831.
10.2.8.5 Reporting of DILI
If a subject is noted to have ALT or AST elevated >3 × UL N on 2 consecutive occasions, the 
abnorm ality shoul d be recorded as an AE. In addit ion, a DILI eCRF must be completed providing 
additional information on rel evant recent history , risk factors, clinical signs and symptoms and 
resul ts of any addit ional diagn ostic tests perform ed.
If a subject is noted to have ALT or AST elevated >3 × ULN on 2 consecutive occasions, the 
abnorm ality shoul d be recorded as an AE. In addit ion, a DILI eCRF must be completed providing 
additional information on rel evant recent histor y, risk factors, clinical signs and symptoms and 
resul ts of any addit ional diagnost ic tests performed.
If a subject is noted to have ALT or AST >3 × ULN and total bilirubin >2 × ULN for which an 
alternat ive etio logy has not been i dentified, the event shoul d be recorded as an SAE and reported 
as per Secti on  10.2.8.3 . The i nvest igator must contact the Medical Monitor for discussio n of the 
relevant subje ct details and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute liver disease. Follow -up laboratory  tests as described in Section  9.2.15 must also be 
perform ed. In addi tion, a DILI eCRF must be completed and transmitted with the Takeda SAE 
form (as per Secti on  10.2.9 ). 
10.2.9 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The Sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, invest igators and IRBs or 
IECs, as a pplicable, in accordance with nat ional regulat ions in the countries where the study  is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the Sponsor or 
Sponsor’s designee, SUSARs will be submitted within 7 days for fatal an d life -threatening events 
and 15 days for other serious events, unless otherwise required by nat ional regulat ions. The 
Sponsor will also prepare an expedited report for other safety issues where these might materially 
alter the current benefit -risk assessm ent of  an investigat ional medicinal product or that would be 
sufficient to consider changes in the investigat ional medicinal products administration or in the 
overall conduct of the study . The invest igational site al so will forward a copy  of all expedited 
reports to his or her IRB or IEC in accordance wit h national regulat ions.
TAK -831
Study No. TAK -831-2001 Page 59of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized prior to unblinding of treatment 
assignments to the study team. This document will provide further details regarding the definit ion 
of analysis variables and analysis methodology  to address a ll study  object ives. In cases of 
inconsistencies between the protocol and the SAP in regard to data analysis, the SAP is to take 
precedence over the protocol. Due to this clear understanding of precedence, the statist ical analysis 
section will not necessar ily be updated to m atch the SAP when the protocol is amended.
A targeted data review will be conducted prior to unblinding of treatment assignments to the study 
team . This review will assess the accuracy  and completeness of the study  database, subject 
evaluabili ty, and appropri ateness of the planned statist ical methods .
11.1.1 Analysis Sets
11.1.1.1 Safety Set
The Safety Set will include all randomized subjects who receive at least 1 dose of double -blind study  
medication. Subjects in this analysis set will be used for demo graphic, baseline characterist ics, and 
safet y summaries.
11.1.1.2 PK Set
The PK Set will include all randomized subjects who receive at least one dose of double -blind study 
medication and who have any available plasma concentration data .
11.1.1.3 PD Set
The PD set will cons ist of all subjects who receive at least 1 dose of study drug and have at least 1 
postdose PD result.
11.1.2 Analysis of Demographics and Other Baseline Characteristics
Dem ographics and baseline characterist ics including age, gender, race, body  mass index, and 
medical history  will be listed and summarized by randomized treatment sequence and overall 
based on the Safet y Set.
Baseline values for selected PD assessments will also be summarized by treatment sequence and 
overall based on the Safety  Set.
11.1.3 PK Analysis
Plasma concentrations o f TAK -831 will be listed for each subject and summarized by each time 
point for each dose and period of the study . 
Individual concentration -time data will be pooled to describe the populat ion PK of TAK -831. As 
data permit, a nonlinear mixed effects modeling approach (NONMEM software) will be used to 
TAK -831
Study No. TAK -831-2001 Page 60of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALassess TAK -831 exposure. PK information generated in this study  will be further utilized in 
subsequent popul ation PK -PD analyses. The relat ionships between TAK -831 pl asma 
concentrations and drug response will be explored. As appropriate, historical data may  be used in 
this analysis to increase the robustness o f the model and precisio n of estimated pa rameters. Details 
of the m odeling approach will be provided in a separate analysis plan, and the results of these 
analyses may be reported separately.
11.1.4 PD Analysis 
11.1.4.1 Analysis of Primary PD Endpoint 
Pairwise com parisons between act ive treatments and placebo will be generated within the 
framework of analysis of variance (ANOVA), with treatment sequence, period, and treatment as 
fixed effects. Subject nested within sequence is included as a rando m effect. The dependent 
variable is the change in response fro m the peri od baseline assessment to the final treatment day  
for each period. The analysis will be performed using observed data. Poten tial carry over effects 
will be invest igated. P -values and confidence intervals will be reported.
A frequent ist analysis will b e done for the full data set, using simulat ions to adjust for the effect of 
the interim analysis on the type I error rates. The results of the primary endpo int will be considered 
statist ically significant at either of the 2 doses (as applicable) if the one -sided p<0.05, without 
adjustm ent for multiplicity (ie, the ty pe I error rate will be separately controlled for each dose). 
In addit ion, the primary  endpoint will  be analyzed using a Bayesian normal linear model with 
treatm ent sequence, period, and treatm ent as fixed effects and subject within sequence as a 
repeated factor. The dependent variable is the change in response fro m the period baseline 
assessment to the final treatment day  for each period. The response data will be logit transformed 
before the c hange is calculated. A diffuse normal distribut ion will be used as a prior for the 
regression coefficients and a diffuse inverse gamma for the residual variance. The Bayesian mode l 
will be used to estimate the posterior distribut ion of the treatment effect from each dose (as 
applicable) . 
11.1.4.2 Analysis of Other PD Endpoints 
The secondary  EEG endpoints will be analyzed using an ANOVA model as described in 
Secti on11.1.4.1 . 
The cognit ive battery  com posite score, the BACS, will be analyzed as follows. The primary  
measure fro m each test is standardized by creat ing z -scores whereby the mean of the test sessio n of 
a healt hy participant is set to 0 and the standard deviat ion set to 1 [44]. A composite score will be 
calculated by averaging the 4 measures from the BACS used in the study , and then calculat ing a
z-score of the composite. The composite z -score indi cates how m uch higher or l ower the 
participant’s cognit ion is co mpared to a healthy person. An ANOVA will be performed on the 
change from baseline for the composite BACS score, using a similar model to t hat used for 
primary  endpoint.
TAK -831
Study No. TAK -831-2001 Page 61of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALFor each regimen, the concentrations of D -serine, L -serine, and the ratio of D -serine to total serine 
with change and percent change fro m Baseline will be summarized at each t ime po int of each dose 
level using descript ive sta tistics. In addit ion, mixed effects regressio n models will be fitted to the 
change from Baseline in these concentrations. Pairwise comparisons between the test regimens 
(high dose, low dose and placebo) will be made and the CIs for the difference in the LS means will 
be constructed for selected time po ints. Addit ional details and further analyses will be specified in 
the stati stical analysis plan.
There will be no adjust ment for the m ultiplicity of secondary  endpoints.
Analysis of exploratory  PD endpo ints will be described in the SAP.
11.1.5 Safety Analysis
The Safet y Set will be used for all summaries of safet y param eters. These summaries will be 
presented by cohort for placebo, each TAK -831 dose level, and TAK -831 overall (as appropriate). 
11.1.5.1 AEs
All AEs will be co ded by  system  organ cl ass (SOC) and preferred term (PT) using the Medical 
Dictionary for Regulatory  Activities (MedDRA). TEAEs with onset occurring within 30 days 
(onset date – last date of dose +1 ≤30) after study drug administration will be included in th e 
summary tables. All AEs will be in the list ings. TEAEs will be summarized by SOC and PT. The 
following summary  tables will be incl uded in the report: summary of TEAEs and drug- related 
AEs, rel ationship of AEs to study  drug (rel ated vs not rel ated), sever ity of AEs, and related AEs. 
Data list ings will be provided for all AEs including TEAEs, AEs leading to study  drug 
discontinuat ion, and SAEs.
11.1.5.2 Clinical Laboratory Evaluation
Individual result s of l aboratory  tests fro m hematology , chemistry , and urinalysis t hat meet 
Takeda’s markedly abnormal criteria will be summarized and provided in the data list ings. 
Baseline, postdose, and change from Baseline to postdose laboratory data will be summarized. All 
clinical laboratory  data will be provi ded in the data list ings.
11.1.5.3 Vital Signs
Individual result s of vital signs that meet Takeda’s markedly abnormal criteria will be summarized 
and provided in the data list ings. Baseline, postdose, and changes fro m Baseline in vital sign 
measurements will be summarized. All vital sig n data will be provided in the data list ings.
11.1.5.4 ECGs
Individual result s of quant itative ECG parameters fro m the 12-lead safet y ECGs that m eet 
Takeda’s markedly abnormal criteria will be summarized and provided in the data list ings. 
Baseline, postdose, and changes from Baseline in quant itative ECG parameters will be 
summarized. Shift tables will be generated to show the investigator’s ECG interpretations at each 
postdose collect ion by the interpretation at Baseline.
TAK -831
Study No. TAK -831-2001 Page 62of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALAll ECG data will be provided in the data list ings.
11.1.5.5 Other Safety Parameters
Physical examinat ion findings will be presented in the data list ings.
11.2 Interim Analysis and Criteria for Early Termination
A planned unblinded interim analysis o f the primary  PD endpoints will  be conducted when 
approximately  14 pati ents have been com pleted the primary  endpoin t. The si te will be allo wed to 
continue enrollment to the high/placebo comparison, with the goal that approximately  16 pati ents 
will be rando mized by the time the interim analysis is co mplete. (The addit ional 
approximately 2subjects will be included in th e final analysis but not the interim analysis.) The 
purpose of the interim PD analysis will be to determine whether to con tinue enro lling subjects to 
the high -dose/placebo com parison, switch enro llment to the low -dose/pl acebo com parison, or 
discontinue enr ollment. The decisio n rule will be specified in an interim analysis plan before the 
data are unblinded for the interim analysis. In addit ion, a decisio n to switch to the low dose may be 
made based on safet y or tol erabilit y of the high dose .
11.3 Determination of Sample Size
Up to approximately  32 subjects will be enrolled into this 2- period crossover study .Initially 
16subjects will be rando mized to 1 of 2 sequences comparing the high dose to placebo. Based on 
the results of an interim analysis, an addit ional 1 6 subjects may be rando mized as before or to 1 of 
the 2 sequences comparing the low dose to placebo. 
The expected effect size, defined as the ratio between the mean difference between treatment and 
placebo divided by the standard deviat ion of this differe nce, is 0.6 for the primary endpo int. This 
effect size is a conservat ive est imate based on data fro m [20], which showed an effect size o f 0.74 
for EBC at 24 hours after init iation of treatment with secretin. In this study  of a schizophrenic 
popul ation, subjects on secretin showed a 24% higher rate of correct responses compared to 
subjects on placebo (70% vs 46%).
The sample sizes o f 16 or 32 subjects have been selected to enable Bayesian analyses to inform 
dose sel ection and future drug development under the expected effect size as well as other 
plausible effect si zes.
TAK -831
Study No. TAK -831-2001 Page 63of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL12.0 QUALITY CONTROL AND QUALITY ASSURANCE
12.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and study site guarantee access to source documents by the Sponsor or it s 
designee (CRO) and by  the IRB or IEC.
All aspects of the study  and i ts docum entati on will be subject to review by the Sponsor or the 
Sponsor’s designee (as lo ng as blinding is not jeopardized), including but not limited to the 
Invest igator’s Binder, stud y drug, subject medical records, informed consent documentation, and 
review of eCRFs and associated source documents. It is important that the invest igator and other 
study  personnel are available during the monitoring visits and that sufficient time is dev oted to the 
process.
12.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the subject, or confound interpretation of primary study  assessment. 
12.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also may  be subject to qualit y assurance audi ts by  the Sponsor or designees. In this 
circumstance, the Sponsor -designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the fac ilities where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
the US Food and Drug Administration (FDA), the United Kingdom Medicines and Healt hcare 
Products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan. If the 
study  site is contacted for an inspect ion by a regulatory  body , the Sponsor should be not ified 
immediately . The investi gator guarantees access for qualit y assurance auditors to all study  
docum ents as described in Sect ion  12.1.
TAK -831
Study No. TAK -831-2001 Page 64of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL13.0 ETHICAL ASPECTS OF T HE STU DY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the International Conference on Harmo nisat ion (ICH) Harm onised Tri partite 
Guideline for GCP. Each investigator will conduct the study  according to applicable local or 
regional regulatory  requi rements and align his or her conduct in accordance wit h the 
“Responsibilit ies of the Investigator” that are listed in Appendix A. The principles of Helsinki are 
addressed through the protocol and through appendices containing requirements for informed 
consent and invest igator responsibilit ies.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing region. The Sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those Americas sites unwilling to provide names a nd titles of  all 
members due to privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The Sponsor or designee will supply  relevant docu ments for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy o f 
the informed consent form, and, if applicable, subject recruit ment materials and/or advertisements 
and other doc uments required by all applicable laws and regulations, must be submitted to a 
central  or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the Sponsor or desig nee before 
commencement of the study  (ie, before shipment of the Sponsor -supplied drug or study  specific 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; ident ify versio ns of other docume nts (eg, informed consent form) 
reviewed; and state the approval date. The Sponsor will ship drug/notify site once the Sponsor has 
confirmed the adequacy of site regulatory  docum entati on and, when applicable, the Sponsor has 
received permissio n from competent authori ty to begin the study . Until the si te receives 
drug/notificat ion no protocol activit ies, including screening, may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tment m aterials intended for viewing by  subjects, l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by the 
respective IRB or IEC, and submissio n of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
Sponsor or i ts desi gnee.
Subject incentives should not exert un due influence for participat ion. Payments to subjects must 
be approved by the IRB or IEC and Sponsor.
TAK -831
Study No. TAK -831-2001 Page 65of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL13.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in th e 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the p lanned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and, if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the Sponsor prior to use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informa tion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable) , and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adequat e wri tten inform ed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given amp le opportunit y to: 
(1) inquire about details o f the study, and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informed consent form  and subject authorizat ion form (if applicable) m ust be 
signed and dated by  the subject, or the subject’s legally  acceptable representative, at the time of 
consent and prior to the subject entering into the study . The subject or the subject’s l egally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e tim e of consent and pri or to subject entering 
into the study; however, the Sponsor may allow a designee of the invest igator to sign to the extent 
permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if appl icable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent for m, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
TAK -831
Study No. TAK -831-2001 Page 66of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALAll revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
 
 Notify 
Sponsor of consent withdrawal.
13.3 Subject Confidentiality
The Sponsor and desi gnees affi rm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the Sponsor’s clinical study  database or documentation via a unique ident ificat ionnumber. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To comply wit h ICH Guidelines for GCP and to verify co mpliance with this protocol, the Sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the Sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports , ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 13.2).
Copi es of  any subject source documents that are provided to the Sponsor must have certain 
personally ide ntifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
13.4 Publication, Disclosure, and Clinical Study Registration Policy
13.4.1 Publication and Disclosure
The invest igator is obliged to provide th e Sponsor wi th com plete test resul ts and all  data derived 
by the investigator from the study . During and after the study , only  the Sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is t he sole responsibilit y of the Sponsor.
The Sponsor may publish any data and information fro m the study (including data and informat ion 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publi cation will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 

TAK -831
Study No. TAK -831-2001 Page 67of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALthis secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Study Registration 
In order to ensure that information on clinical studies reaches the public in a timely manner and to 
comply with applicable la ws, regul ations and guidance, Takeda will, at a minimum register all 
intervent ional clinical studies it Sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along wi th invest igator’s cit y, state (for investigators in the United States), 
country , and recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist caller s in l ocating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone number to the callers request ing study  
inform ation. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the study . The invest igative sites are encouraged to handle the study 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of study  enro llment, th ey shoul d be referred to the Spo nsor.
Any investigator who objects to the Sponsor providing this informat ion to callers must provide the 
Sponsor with a written notice requesting that their informat ion not be listed on the registry  site.
13.4.3 Clinical Study Results Disclosure 
Takeda will post the results of clinical studies on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
13.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in acco rdance wi th the regulations applicable to the site 
where the subject is part icipating. If a local underwriter is required, then the Sponsor or Sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to study  subjects. Refer to 
the study site agreement regarding the Sponsor’s policy on subject compensat ion and treatment for 
injury . If the investigator has quest ions regarding this po licy, he or she should contact the Sponsor 
or Sponsor’s designee.
TAK -831
Study No. TAK -831-2001 Page 68of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL14.0 ADMINISTRATIVE AND REFERENCE INFORM ATION
14.1 Administrative Information
14.1.1 Study Contact Information 
Contact Type / Role Contact
SAE and pregnancy reporting Takeda Pharmacovigilance
Takeda Development Center Americas, Inc 
Fax: 224 -554- 1052
Email: PVSafetyAmericas@tpna.com
TAK -831
Study No. TAK -831-2001 Page 69of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL14.1.2 INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
insert and any other product informat ion provi ded by  the Sponsor. I agree to conduct this study  in 
accordance with the requirements of this prot ocol and also to protect the rights, safet y, privacy, 
and well -being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting SAEs defined in Section 10.2.9 of this protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator (Appendix A).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in  Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
14.1.3 Study -Related Responsibilities 
The Sponsor will perform all study -related acti vities wi th the excepti on of  those i dentified in the 
Study -Related Responsibilit ies template. The vendors i dentified for specific study -related 
activit ies will perform these act ivities in full or in partnership wi th the Sponsor.
TAK -831
Study No. TAK -831-2001 Page 70of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL14.1.4 List of A bbreviations
AE adverse event
AIMS Abnormal Involuntary Movement Scale
ALT alanine aminotransferase
AMPA α-amino -3-hydroxy -5-methy l-4-isoxazole propionic acid
AST aspartate aminotransferase
ASSR auditory  steady -state response
ANOVA analy sis of variance
BACS Brief Assessment of Cognition in Schizophrenia
beta-hCG beta human chorionic gonadotropin
BMI body mass index
CDSS Calgary  Depression Scale Score
CIAS cognitive impairment in schizophrenia
CRO contract research organization
CR conditio ned response
CS conditio ned stimulus
C-SSRS Columbia Suicide Severity Rating Scale 
Cz midline central electrode
DAO D-amino acid oxidase
DNA deoxyribonucleic acid
DSM -5 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
EBC eyeblink conditioning
ECG electrocardiogram
eCRF electronic case report form
EEG electroencephalography
EDS extra -dimensional set shifting
ERP event related potential
FDA Food and Drug Administration of the United States
FSH follicle stimulating hormone 
Fz midline f rontal electrode
GCP Good Clinical Practice
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HPLC high performance liquid chromatography
HIV human immunodeficiency virus
HR heart rate
ICH International Conference on Harmonisation
IDS intra-dimensional shift
IEC Independent Ethics Committee
IRB institutional review board
IRT interactive response technology
TAK -831
Study No. TAK -831-2001 Page 71of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALK2EDTA Potassium ethylenediaminetetraacetic acid
LFT liver function test
MedDRA Medical Dictionary for Regulatory Activities
MMN mismatch negativity
MOP manual of procedure
MRD multiple -rising dose
NMDA N-methy l-D-aspartate
NSFS negative symptom factor score
PANSS Positive and Negative Symptom Scale
PCP phencyclidine
PD pharmacodynamics
PET positron emission tomography
PK pharmacokinetic
PT preferred term
Pz midline parietal electrode
QD once daily
QTcF QT interval with Frederica correction method
RNA ribonucleic acid
Rs resting state
SAE serious adverse event
SAP statistical analysis plan
SAS Simpson Angus Scale
SBP systolic blood pressure
SOC system organ class
SRD single -rising dose
SUSAR suspected unexpected serious adverse reactions
TEAE treatment -emergent adverse event
ULN upper limit of normal
US unconditioned response
WBC white blood cell

TAK -831
Study No. TAK -831-2001 Page 72of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL15.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, m edical history , and concurrent conditions will be coded using the MedDRA. Drugs will be 
coded using the World Healt h Organizat ion Drug Di ctionary.
15.1 CRFs (Electronic and Paper)
Com pleted eCRFs are required for each subject who signs an informed consent.
The Sponsor or its designee will supply invest igativesites wi th access to eCRFs. The Sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the Sponsor and regulatory  
authori ties. e CRFs must be completed in English. Data are transcribed direct ly onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issue d by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be included. 
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the inv estigator m ust retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the eCRFs should be made by the investig ator wi th use of change and modificat ion records of 
the eCRFs. The principal investigator must review the data change for completeness and accuracy, 
and must sign and date . 
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during periodic visi ts 
by study  monitors. The Sponsor or i ts desi gnee will  be permi tted to revi ew the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the Sponsor and shou ld not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the Sponsor.
15.2 Record Retention
The invest igator agrees to keep the recor ds sti pulated in Secti on  15.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the inform ed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the Sponsor or its designees. Any source 
TAK -831
Study No. TAK -831-2001 Page 73of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALdocum entati on printed on degrad able thermal sensitive paper should be photocopied by the site 
and filed wit h the original in the subject’s chart to ensure long -term legibilit y. Furthermore, ICH 
E6 Secti on 4.9.5 requi res the investigator to retain essent ial docum ents specified in ICH E6 
(Secti on 8) until at least 2 y ears after the last approval of a market ing applicat ion for a specified 
drug indicat ion being investigated or, if an applicatio n is not approved, until at least 2 years after 
the invest igation is discontinued and regulatory au thorities are notified. In addit ion, ICH E6 
Secti on 4.9.5 states that the study  records should be retained unt il an am ount of time specified by  
applicable regulatory  requi rements or for a time specified in the Clinical Study  Site Agreement 
between the inve stigator and Sponsor.
Refer to the Clinical Study  Site Agreement for the Sponsor’s requirements on record retention. 
The invest igator and the head o f the inst itution shoul d contact and receive written approval from 
the Sponsor before disposing of any  such docum ents.
TAK -831
Study No. TAK -831-2001 Page 74of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL16.0 REFERENCES
1.Sham PC, Gottesman, II, MacLean CJ, Kendler KS. Schizophrenia: sex and familial 
morbidity. Psychiatry  Res 1994;52(2):125 -34.
2.Cardno AG, Marshall EJ, Coid B, Macdonald AM, Ribchester TR, Davies NJ, et al. 
Heritabili ty estimates for psy choti c disorders: the Maudsley twin psychosis series. Arch Gen 
Psychiatry  1999;56(2):162 -8.
3.Erlenmeyer -Kimling L, Squires -Wheeler E, Adamo UH, Bassett AS, Cornblatt BA, 
Kestenbaum CJ, et al. The New York High -Risk Proj ect. Psychoses and cluster A personalit y 
disorders in offspring o f schizophrenic parents at 23 years of fo llow-up. Arch Gen Psychiatry  
1995;52(10):857 -65.
4.van Os J, Kapur S. Schizophrenia. Lancet 2009;374(9690):635 -45.
5.Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, et al. Imaging 
glutam ate in schizophrenia: review of findings and implicat ions for drug discovery . Mol  
Psychiatry  2014;19(1):20-9.
6.Krystal JH, D'Souza DC, Mathalon D, Perry  E, Belger A, Hoffman R. NMDA receptor 
antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift  
in medicat ion development. Psychopharmaco logy (Berl ) 2003;169(3- 4):215 -33.
7.Calcia MA, Madeira C, Alheira FV, Silva TC, Tannos FM, Vargas -Lopes C, et al. Plasma 
levels o f D-serine in Brazilian individuals wit h schizophrenia. Schizophr Res 
2012;142(1 -3):83 -7.
8.Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, et al. Changes in plasma 
glycine, L -serine, and D -serine levels in pat ients with schizoph renia as their clinical symptoms 
improve: results from the Juntendo Universit y Schizophrenia Proj ects (JUSP). Prog 
Neuropsychopharmaco l Biol Psychiatry  2008;32(8):1905 -12.
9.Hashimoto K, Fukushima T, Shimizu E, Ko matsu N, Watanabe H, Shinoda N, et al. Decreased 
serum  levels of D -serine in pat ients with schizophrenia: evidence in support of the 
N-methyl-D- aspartate receptor hy pofunction hypothesis of schizophrenia. Arch Gen 
Psychiatry  2003;60(6):572 -6.
10.Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindst rom LH, Iy o M. Reduced D -serine to 
total serine rati o in the cerebrospinal fluid o f drug naive schizophrenic pat ients. Prog 
Neuropsychopharmaco l Biol Psychiatry  2005;29(5):767 -9.
11.Schizophrenia Working Group of the Psy chiatri c Geno mics Consortium. Bio logical insights 
from 108 schizophrenia- associ ated genet ic loci. Nature 2014;511(7510):421-7.
12.Verrall L, Burnet PW, Betts JF, Harrison PJ. The neurobiology of D -amino acid oxidase and its 
involvement in schizophrenia. Mo l Psychiatry 2010;15(2):122 -37.
TAK -831
Study No. TAK -831-2001 Page 75of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL13.Kakegawa W, Miyoshi Y, Hamase K, Matsuda S, Matsuda K, Kohda K, et al. D -serine 
regul ates cerebellar LTD and motor coordination through the delta2 glutamate receptor. Nat 
Neurosci 2011;14(5):603-11.
14.Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, C hen PW, et al. Add -on treatm ent of 
benzoate for schizophrenia: a rando mized, double -blind, pl acebo -controlled trial o f D-amino 
acid oxidase inhibitor. JAMA Psychiatry  2013;70(12):1267 -75.
15.Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA , et al . The 
Columbia -Suicide Severit y Rat ing Scale: init ial validit y and internal consistency findings fro m 
three m ultisite studi es wi th adol escents and adults. Am J Psychiatry  2011;168(12):1266-77.
16.Radi ZA, Stewart ZS, Grzemski FA, Bobrowski WF. Rena l pathophysio logic rol e of corti cal 
tubul ar inclusi on bodi es. Toxi col Pathol  2013;41(1):32 -7.
17.Forsy th JK, Bolbecker AR, Mehta CS, Klaunig MJ, Steinmetz JE, O'Donnell BF, et al. 
Cerebellar -dependent ey eblink condi tioning deficit s in schizophrenia spectr um disorders. 
Schizophr Bull 2012;38(4):751 -9.
18.Yang Y, Lei C, Feng H, Sui JF. The neural circuitry and mo lecular mechanisms underlying 
delay and trace ey eblink condi tioning in mice. Behav Brain Res 2015;278:307-14.
19.Kent JS, Bolbecker AR, O'Donnell BF, Hetri ck WP. Eyeblink Condit ioning in Schizophrenia: 
A Crit ical Review. Front Psy chiatry  2015;6:146.
20.Bolbecker AR, Hetrick WP, Johannesen JK, O'Donnell BF, Steinmetz JE, Shekhar AS. 
Secretin effects on cerebellar -dependent motor learning in schizoph renia. Am J Psychiatry  
2009;166(4):460 -6.
21.Umbricht D, Schmid L, Ko ller R, Vollenweider FX, Hell D, Javitt DC. Ketamine -induced 
deficits in auditory  and visual context -dependent processing in healt hy vo lunteers: 
implicat ions for models of cogni tive defi cits in schizophrenia. Arch Gen Psychiatry  
2000;57(12):1139 -47.
22.Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negat ivity predicts psychoti c 
experiences induced by NMDA receptor antagonist in healt hy vo lunteers. Bi ol Psychiatry  
2002;51(5):40 0-6.
23.Thune H, Recasens M, Uhlhaas PJ. The 40 -Hz Audi tory Steady -State Response in Patients 
With Schizophrenia: A Meta- analysis. JAMA Psychiatry  2016;73(11):1145-53.
24.Sivarao DV, Chen P, Senapati A, Yang Y, Fernandes A, Benitex Y, et al. 40 Hz Audito ry 
Steady -State Response Is a Pharmacodynamic Bio marker for Cortical NMDA Receptors. 
Neuropsychopharmaco logy 2016;41(9):2232-40.
25.Light GA, Swerdl ow NR, Thom as ML, Calkins ME, Green MF, Greenwood TA, et al. 
Validat ion of mismatch negat ivity and P3a for use in multi-site studi es of schizophrenia: 
characterizat ion of demographic, clinical, cognit ive, and functional correlates in COGS- 2. 
Schizophr Res 2015;163(1 -3):63 -72.
TAK -831
Study No. TAK -831-2001 Page 76of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL26.Light GA, Swerdlow NR. Future clinical uses of neurophysio logical  biomarkers to pr edict and 
monitor treatm ent response for schizophrenia. Ann N Y Acad Sci 2015;1344:105 -19.
27.Light GA, Braff DL. Stabilit y of mismatch negat ivity defici ts and thei r relati onship to 
funct ional impairments in chronic schizophrenia. Am J Psychiatry  2005;162 (9):1741 -3.
28.Light GA, Swerdl ow NR, Ri ssling AJ, Radant A, Sugar CA, Sprock J, et al. Characterizat ion 
of neurophysio logic and neurocognit ive biomarkers for use in geno mic and clinical outcome 
studi es of  schizophrenia. PLoS One 2012;7(7):e39434.
29.McFadden KL, Steinmetz SE, Carroll AM, Simo n ST, Wallace A, Rojas DC. Test -retest 
reliabilit y of the 40 Hz EEG auditory  steady -state response. PLoS One 2014;9(1):e85748.
30. Tan HR, Gross J, Uhlhaas PJ. MEG- measured auditory  steady -state oscillat ions show high 
test-retest reliabilit y: A sensor and source -space analysis. Neuroimage 2015;122:417 -26.
31.Timmann D, Drepper J, Frings M, Maschke M, Richter S, Gerwig M, et al. The human 
cerebellum contributes to motor, emotional and cognit ive associative learning . A review. 
Cortex 2010;46(7):845 -57.
32.Timmann D, Drepper J, Calabrese S, Burgerhoff K, Maschke M, Kolb FP, et al. Use of 
sequence informat ion in associat ive learning in control subjects and cerebellar pat ients. 
Cerebellum 2004;3(2):75-82.
33.Chen H, W ang YJ, Yang L, Sui JF, Hu ZA, Hu B. Theta synchronizat ion between medial 
prefrontal cortex and cerebellum is associated with adaptive performance of associat ive 
learning behavior. Sci Rep 2016;6:20960.
34.Dalal SS, Osi pova D, Bertrand O, Jerbi K. Oscilla tory activit y of the human cerebellum: the 
intracranial  electrocerebellogram revisited. Neurosci Bio behav Rev 2013;37(4):585-93.
35.Koziol LF, Budding D, Andreasen N, D'Arrigo S, Bulgheroni S, Imamizu H, et al. Consensus 
paper: the cerebellum's ro le in movement and cognit ion. Cerebellum 2014;13(1):151 -77.
36.Simpson GM, Angus JW. A rat ing scale for extrapyramidal side effects. Acta Psychiatr Scand 
Suppl  1970;212:11-9.
37.Guy W. Abnormal Invo luntary Movement Scale (AIMS). In: EDCEU Assessment Manual for 
Psychopharm acology -Revised (DHEW Publ No ADM 76 -338). Rockville, MD: U.S. 
Departm ent of Healt h, Educati on, and Welfare, Public Healt h Service, Alcoho l, Drug Abuse, 
and Mental Healt h Administration, NIMH Psychopharmaco logy Research Branch, Divisio n of 
Extramural Research Programs; 1976, p. 534- 7.
38.Munetz MR, Benjamin S. How to examine subjects using the Abnormal Invo luntary 
Movement Scale. Hospital and Co mmunit y Psychiatry  1988;39:1172 -7.
39.Kay SR, Opler LA, Fisbein A. Posit ive and Negat ive Syndro me Sc ale Manual. North 
Tonawanda, NY: Mult i-Health System s; 1994.
40.Oplar LA, Kay SSR, Lindenmayer JP, Fiszbein A. Structured Clinical Interview for the 
Positive and Negat ive Syndro me Scale (SCI -PANSS). Toronto: Mult i-Health Systems; 1992.
TAK -831
Study No. TAK -831-2001 Page 77of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL41.Perkins DO, Stroup TS, Lieberman JA. Psychotic disorders measures. In: Handbook of 
Psychiatri c Measures. Washington, DC: American Psy chiatri c Associ ation; 2000, p. 485- 513.
42.Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment 
of Cognition in Schizophrenia: reliabilit y, sensi tivity, and com parison wi th a standard 
neurocognit ive battery. Schizophr Res 2004;68(2 -3):283 -97.
43.Atkins AS, Tseng T, Vaughan A, Twamley EW, Harvey P, Patterson T, et al. Validation of the 
tablet-administered Brief Assessment of Cognit ion (BAC App). Schizophr Res 
2017;181:100 -6.
44.Keefe RS, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, et al. Norms and 
standardization o f the Brief Assessment of Cognit ion in Schizophrenia (BACS). Schizophr 
Res 2008;10 2(1-3):108 -15.
45.Doyle OM, De Simo ni S, Schwarz AJ, Brittain C, O'Daly OG, Williams SC, et al. Quant ifying 
the attenuation of the ketamine pharmaco logical magnet ic resonance imaging response in 
humans: a validat ion using ant ipsychotic and glutamatergic a gents. J Pharm acol Exp Ther 
2013;345(1):151 -60.
46.Rasmussen CE, Williams KI. A Pictorial Introductio n to Bay esian Modelling. In: Gaussian 
Processes for Machine Learning. Cambridge, MA: Massachusetts Inst itute of Techno logy 
Press; 2006; Chapter 1, p. 1 -6.
TAK -831
Study No. TAK -831-2001 Page 78of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL17.0 APPENDICES
Appendix AResponsibilities of the Investigator
Clinical research studies sponsored by  the Sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on inve stigators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form  FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es an d functions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions perform ed and any 
data generated.
4.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies/authori ties.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and loca l regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least yearly reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9.Obtain valid inform ed consent from  each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each informed consent form should contain a subject 
authorization sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorizat ion, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, l aboratory  resul ts, etc, and maintain these data for a minimum o f 
TAK -831
Study No. TAK -831-2001 Page 79of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL2years fo llowing notificat ion by the Sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator shoul d 
contact and receive written approval fro m the Sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, adminis tration, and disposi tion of  Sponsor -supplied 
drugs, and return all unused Sponsor -supplied drugs to the Sponsor. 
13. Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor 
within 24 hours.
TAK -831
Study No. TAK -831-2001 Page 80of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALAppendix BElements of the Subject Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3. The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject ’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11. A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When t here is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  signing a wri tten informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , tothe subject for participat ing in the study.
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
19.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the subject otherwise is ent itled, and that the subject or the subject’s 
TAK -831
Study No. TAK -831-2001 Page 81of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALlegally acceptable representative may discont inue partic ipation at any  time wi thout penal ty or 
loss of benefit s to whi ch the subject is otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement t hat the subject or the subject’s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the study .
22.  
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit hercontained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of co nduct ing the study. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferr ed to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and lic ensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws t hat offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawa l from the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.

TAK -831
Study No. TAK -831-2001 Page 82of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIAL25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually  active m ust use highly  effect ive contraception (as defined in the informed 
consent) from signing the informed consent and throughout the duration of the stu dy, and for 
35 days after the last dose of study drug. Regular pregnancy tests will be performed throughout 
the study  for all female subjects of childbearing potential. If a subject is found to be pregnant 
during study , study  drug will be discont inued and the invest igator will o ffer the subject the 
choice to receive unblinded treatment informat ion. 
26.Male subjects must use a barrier method of contraception (eg, condom wit h or without 
spermicide) as defined in the informed consent from signing the informed co nsent throughout 
the duration of the study and for 95 days after the last dose of study drug. If the partner or wife 
of the subject is found to be pregnant during the study, the invest igator will offer the subject the 
choice to receive unblinded treatment informat ion. 
27.A statem ent that clinical trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
TAK -831
Study No. TAK -831-2001 Page 83of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALAppendix CInvestigator Consent to Use of Personal Information
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countr ies throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studi es that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiv ing and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the pu rposes described above.
TAK -831
Study No. TAK -831-2001 Page 84of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALAppendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Male Subjects and Their Female Partners
From  signing of informed consent, throughout the duration of the study , and for 95 days after l ast 
dose of study drug, nonsterilized** male subjects who are sexually act ive with a female partner of 
childbearing potential* must use barrier contraceptio n (eg, condom wit h or without spermicidal 
cream  or jelly). In addit ion, they  must be advised not to donate sperm during this period. Females 
of childbearing potential who are partners of male subjects are also advised to use addit ional 
contraception as shown in the list containing highly  effect ive/effect ive contraception below.
Femal e Subjects and Their Male Partners
From  signing of informed consent, throughout the duration of the study , and for 35 days after last 
dose of study  drug, female subjects of childbearing potential* who are sexually  active wi th a 
nonsterilized male partner** must use a hi ghly effective/effect ive method of contraception (fro m 
the list below). 
For studies in which teratogenicit y/genotoxi city/embry otoxi city has been demo nstrated 
(invest igational medicinal product or comparator or background medicat ion), or ther e is a lack of 
adequate reproductive toxicit y data, f emale subjects should be instructed to use two highly  
effect ive methods of contraception/one highly  effective and one effect ive method (fro m the list 
below). 
In addit ion they  must be advised not to dona te ova during this period.
Definitions and Procedures for Contraception and Pregnancy Avoidance
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
* A wom an is considered a woman of childbearing potential, ie, fert ile, fo llowing menarche and 
until becoming post -menopausal unless permanently  sterile. Perm anent sterilizat ion methods 
include hysterectomy, and bilateral oophorectomy . A postmenopausal state is defined as no 
menses for 12 months wit hout an alternative medical ca use. A FSH l evel in the postm enopausal 
range (FSH >40 IU/L) may be used to confirm a post- menopausal state in y ounger wom en (eg, 
those <45 year old) or women who are not using hormonal contraception or hormonal replacement 
therapy . However, in the absence of 12 m onths of am enorrhea, a single FSH measurement is 
insufficient.
** Sterilized males should be at least 1 year post -bilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or have had bilat eral 
orchi dectomy .
The follow ing procedures apply for contraception and pregnancy avoidance.
1.Highly effect ive methods of contraception are defined as “those, alone or in combinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y earwhen used consistent ly and 
TAK -831
Study No. TAK -831-2001 Page 85of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALcorrectly ). In this study, where medications and devices containing hormones are excluded, the 
only acceptable methods of contraception are: 
Non-Hormonal Methods: 
–Intrauterine device.
–Bilateral tubal occlusio n.
–Vasectomized partner (provi ded that partner is the sole sexual partner of the trial 
participant and that the vasectomized partner has received medical assessment of the 
surgi cal success.
–True sexual abst inence, only if this is in line wit h the preferred and usual lifes tyle of the 
subject. True abst inence is defined as refraining from heterosexual intercourse during 
the entire period of the study, fro m 1 mo nth prior to the first dose until 35 days after last 
dose.
2.Doubl e-barrier method (contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellies or creams PLUS male condo m).
3.Unacceptable methods of contraception are:
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, post -ovulation methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of fema le and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
Sexual abst inence is NOT an acceptable method of contraception.
4.Subjects will be provided with informat ion on e ffective methods of contraception as part of the 
subject informed consent process and will be asked to sign a consent form stating that they  
understand the requirements for avoidance of pregnancy, donation o f ova, and sperm donat ion 
during the course of the study .
5.During the course of the study, regular serum  hCG pregnancy tests will be performed only for 
wom en of childbearing potential and all subjects (male and female) will receive continued 
guidance wi th respect to the avoidance of pregnancy  and sperm  donat ion as part of the study  
procedures. Such guid ance shoul d include a reminder of the fo llowing:
a)Contraceptive requirements of the study
b)Reasons for use of barrier methods (ie, condom) in males with pregnant partners
c)Assessment of subject compliance through questions such as
i.Have you used the contracept ion consistent ly and correctly since the last visit ?
TAK -831
Study No. TAK -831-2001 Page 86of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALii.Have y ou forgotten to use contraception since the last visit ?
iii.Are y our menses l ate (even in wom en wi th irregular or infrequent menstrual cy cles a 
pregnancy test must be performed if the answer is “yes”)
iv.Is there a chance you could be pregnant ?
6.In addit ion to a negative serum hCG pregnancy test at Screening, female subjects of 
childbearing potential must also have confirmed menses in the mo nth before first dosing (no 
delayed menses), a negative serum hCG pregnancy test at predose on Day 1 prior to receiving 
any dose of study medicat ion. In addit ion, subjects must also have a negative serum/urine hCG 
pregnancy test at any  time during the study , if requested by  the clinical  site.
General Guidance With Respec t to the Avoidance of Pregnancy
Such guidance should include a reminder of the fo llowing:
contraceptive requirements of the study .
reasons for use of barrier methods (ie, condom) in males with pregnant partners.
assessment of subject compliance through questions such as:
–Have you used the contraception consistent ly and correctly since the last visit ?
– H ave y ou forgotten to use contraception since the last visit ? 
–Are y our menses l ate (even in wom en wi th irregular or infrequent menstrual cy cles a 
pregnancy test m ust be performed if the answer is “yes”)
–Is there a chance you could be pregnant ?
Pregnancy
Women of childbearing potential will be included in this study .
If any subject is found to be pregnant during the study  she shoul d be wi thdrawn and any 
spon sor-supplied drug and shoul d be immediately discontinued. In addit ion, any pregnancies in the 
partner of a male subject during the study or for 95 days after the last dose should also be recorded 
following authori zation from the subject’s partner. 
Shoul d the pregnancy  occur during or after administration of blinded drug, the invest igator must 
inform  the subject of their right to receive treatment information. If the subject chooses to receive 
unblinded treatment informat ion, the individual blind should be broken by the invest igator. 
Subjects rando mized to placebo need not be fo llowed. 
If the female subject or female partner of a male subject agrees to the primary care physician being 
inform ed, the invest igator should notify the primary care physician that the female subject/female 
partner of the subject was participat ing in a clinical study  at the time she became pregnant and 
provi de details o f the study  drug the subject received (blinded or unblinded, as applicable).
All pregnancies, including female partn ers of male subjects, in subjects on active study  drug 
(including co mparator, if applicable) will be fo llowed up to final outcome, using the pregnancy  
TAK -831
Study No. TAK -831-2001 Page 87of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALform. Pregnancies will remain blinded to the study team. The outcome, including any  premature 
termination , must be reported to the sponsor. An evaluat ion after the birth o f the child will also be 
conducted.
TAK -831
Study No. TAK -831-2001 Page 88of 88
Protocol Incorporating Amendment No. 06 14 January 2020
CONFIDENTIALAppendix EDetailed Description of Amendments to Text
The primary  sections of the protocol affected by the changes in Amend ment No. 06 are indicated. 
The corresponding text has been revised throughout the protocol.
Change 1: Updated entry criteria.
The primary  changes occur in Section  7.0SELECTION AND 
DISCONTINUATION/WITHDRAWAL OF SUBJECTS
Initial 
wording :7.1 Incl usion Criteria
...
3. Be male or a female aged 18 to 50 years, inclusive, at the Screening Visit.
.....
Amended 
or new
wording :7.1 Incl usion Criteria
.....
3. Be male or a female aged 18 to 60 years, inclusive, at the Screening Visit.
....
Rationale for change: Inclusio n criterion 03 revised to increase the maximum subject age from 
50 to 60 years, which will allow for increasing patient recruit ment. 
The fo llowing sect ions also contain this change:
Secti on  1.0STUDY SU MMARY
Secti on 6.1 Study  Design and Descript ion
    
 
  
 
  
 
ELECTRONIC SIGNATURES  
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 
090101d680cbc3f1A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic
Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subjects With
Schizophrenia
